0001140361-21-017113.txt : 20210513 0001140361-21-017113.hdr.sgml : 20210513 20210513070033 ACCESSION NUMBER: 0001140361-21-017113 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210513 DATE AS OF CHANGE: 20210513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDS Biotechnology Corp CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 21917140 BUSINESS ADDRESS: STREET 1: 25B VREELAND ROAD CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 25B VREELAND ROAD CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: Edge Therapeutics, Inc. DATE OF NAME CHANGE: 20090911 10-Q 1 brhc10024337_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from____________to_____________

Commission file number 001-37568

	PDS Biotechnology Corporation
	(Exact name of registrant as specified in its charter)

Delaware		26-4231384
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

	25B Vreeland Road, Suite 300, Florham Park, NJ 07932
	(Address of principal executive offices)

	(800) 208-3343
	(Registrant’s telephone number)


	(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00033 per share		PDSB		Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒

Smaller Reporting Company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s Common Stock, par value $0.00033 per share, outstanding as of May 7, 2021 was 22,278,261.

PDS BIOTECHNOLOGY CORPORATION

FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2021

INDEX

			Page
Part I — Financial Information

	Item 1.	Financial Statements (Unaudited):

		Condensed Consolidated Balance Sheets	1

		Condensed Consolidated Statements of Operations and Comprehensive Loss	2

		Condensed Consolidated Statements of Changes in Stockholders’ Equity	3

		Condensed Consolidated Statements of Cash Flows	4

		Notes to Condensed Consolidated Financial Statements	5

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23

	Item 4.	Controls and Procedures	23

Part II — Other Information

	Item 1.	Legal Proceedings	24

	Item 1A.	Risk Factors	24

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24

	Item 3.	Defaults Upon Senior Securities	24

	Item 4.	Mine Safety Disclosures	24

	Item 5.	Other Information	24

	Item 6.	Exhibits	24

EXHIBIT INDEX			25

SIGNATURES			26

Index

PART 1.

FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

	March 31, 2021			December 31, 2020
ASSETS	(unaudited)
Current assets:
Cash and cash equivalents	$	25,037,374		$	28,839,565
Prepaid expenses and other		2,219,514			1,497,665
Total current assets		27,256,888			30,337,230

Property and equipment, net		3,583			5,443
Operating lease right-to-use asset		501,194			547,706

Total assets	$	27,761,665		$	30,890,379

LIABILITIES AND STOCKHOLDERS’ EQUITY
LIABILITIES
Current liabilities:
Accounts payable	$	950,598		$	1,415,224
Accrued expenses		1,854,795			1,735,322
Operating lease obligation-short term		123,654			119,904
Total current liabilities		2,929,047			3,270,450

Noncurrent liability:
Operating lease obligation-long term		458,291			490,353

Total Liabilities:	$	3,387,338		$	3,760,803


STOCKHOLDERS’ EQUITY
Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2021 and December 31, 2020, 22,278,261 shares and 22,261,619 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively		7,346			7,346
Additional paid-in capital		71,200,684			70,907,315
Accumulated deficit		(46,833,703	)		(43,785,085	)
Total stockholders’ equity		24,374,327			27,129,576

Total liabilities and stockholders’ equity	$	27,761,665		$	30,890,379

See accompanying notes to the condensed consolidated financial statements.

Index

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

	Three Months Ended March 31,
	2021			2020
Operating expenses:
Research and development expenses	$	1,413,057		$	1,971,679
General and administrative expenses		1,636,216			2,060,148

Total operating expenses		3,049,273			4,031,827

Loss from operations		(3,049,273	)		(4,031,827	)

Other income
Interest income		655			46,419

Net loss and comprehensive loss	$	(3,048,618	)	$	(3,985,408	)

Per share information:
Net loss per share, basic	$	(0.14	)	$	(0.39	)
Net loss per share, diluted	$	(0.14	)	$	(0.39	)

Weighted average common shares outstanding, basic		22,263,838			10,314,761
Weighted average common shares outstanding, diluted		22,263,838			10,314,761

See accompanying notes to the condensed consolidated financial statements.

Index

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

	Common Stock				Additional Paid-in Capital
	Shares Issued		Amount		Additional Paid-in Capital		Accumulated Deficit			Total Equity
Balance - December 31, 2019		5,281,237	$	1,742	$	40,633,670	$	(28,937,705	)	$	11,697,707
Stock based compensation expense		–		–		124,992		–			124,992
Issuance of common stock, net of issuance costs		10,000,000		3,299		11,966,703		–			11,970,002
Issuance of common stock for warrant exercise		65,240		22		70,437		–			70,459
Issuance of common stock from 401K match		3,968		1		9,799		–			9,800
Net loss		–		–		–		(3,985,408	)		(3,985,408	)
Balance - March 31, 2020		15,350,445	$	5,064	$	52,805,601	$	(32,923,113	)	$	19,887,552

	Common Stock				Additional Paid-in Capital
	Shares Issued		Amount		Additional Paid-in Capital		Accumulated Deficit			Total Equity
Balance - December 31, 2020		22,261,619	$	7,346	$	70,907,315	$	(43,785,085	)	$	27,129,576
Stock-based compensation expense		–		–		257,622		–			257,622
Issuance of common stock from 401K match		16,642		–		35,747		–			35,747
Net loss		–		–		–		(3,048,618	)		(3,048,618	)
Balance - March 31, 2021		22,278,261	$	7,346	$	71,200,684	$	(46,833,703	)	$	24,374,327

See accompanying notes to the condensed consolidated financial statements.

Index

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Three Months Ended March 31,
	2021			2020
Cash flows from operating activities:
Net loss	$	(3,048,618	)	$	(3,985,408	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		257,622			124,992
Stock-based 401K company common match		35,747			9,800
Depreciation expense		1,860			3,902
Operating lease expense		60,257			-
Changes in assets and liabilities:
Prepaid expenses and other assets		(721,849	)		(570,916	)
Accounts payable		(464,626	)		1,358,983
Accrued expenses		119,473			122,551
Restructuring reserve		-			(228,298	)
Operating lease liabilities		(42,057	)		-

Net cash used in operating activities		(3,802,191	)		(3,164,394	)

Cash flows from financing activities:
Proceeds from exercise of warrants		–			70,459
Proceeds from issuance of common stock, net of issuance costs		–			11,970,002

Net cash provided by financing activities					12,040,461

Net increase (decrease) in cash and cash equivalents		(3,802,191	)		8,876,067
Cash and cash equivalents at beginning of period		28,839,565			12,161,739

Cash and cash equivalents at end of period	$	25,037,374		$	21,037,806

See accompanying notes to the condensed consolidated financial statements.

Index

Note 1 – Nature of Operations

PDS Biotechnology Corporation, a Delaware corporation (the “Company” or “PDS”), is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines designed to overcome the well-established limitations of current immunotherapy technologies. PDS owns Versamune^®, a proprietary T-cell activating platform designed to train the immune system to better attack and destroy disease. When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune^® has been shown to induce, in vivo, large quantities of high-quality, highly potent polyfunctional CD8+ killer T-cells, a specific sub-type of CD8+ killer T-cell that is more effective at killing infected or target cells. Our immuno-oncology products can potentially be used as a component of combination products with other leading technologies to provide effective treatments across a range of cancer types. We believe our product candidates are of interest for potential in relation to Human Papillomavirus, or HPV,- associated cancers, melanoma, colorectal, lung, breast and prostate cancers or as monotherapies in early-stage disease. PDS is working to expand its infectious disease pandemic development program, which includes novel vaccines for COVID-19 and universal influenza.

On March 15, 2019, the Company, then operating as Edge Therapeutics, Inc. (“Edge”), completed its reverse merger with privately held PDS Biotechnology Corporation (“Private PDS”), pursuant to and in accordance with the terms of the Agreement and Plan of Merger, dated as of November 23, 2018, as amended on January 24, 2019, by and among the Company, Echos Merger Sub, a wholly-owned subsidiary of the Company (“Merger Sub”), and Private PDS, whereby Private PDS merged with and into Merger Sub, with Private PDS surviving as the Company’s wholly-owned subsidiary (the “Merger”). In connection with and immediately following completion of the Merger, the Company effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) and changed its corporate name from Edge Therapeutics, Inc. to PDS Biotechnology Corporation, and Private PDS changed its name to PDS Operating Corporation.

For accounting purposes, the Merger was treated as a “reverse acquisition” under generally accepted accounting principles in the United States (“U.S. GAAP”) and Private PDS is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Private PDS became the Company’s historical financial statements, and the historical financial statements of Private PDS are included in the comparative prior periods. As part of the Merger, the Company acquired all of Edge’s assets relating to current and future research and development.

In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a pandemic and on March 13 the President declared a national emergency in response to the pandemic. The full impact of the COVID-19 pandemic is unknown and rapidly evolving. The COVID-19 pandemic has and could continue to negatively affect the Company’s liquidity and operations. To date, two of the three recently initiated PDS0101 clinical trials were delayed, specifically as a result of the adverse impact the COVID-19 pandemic has had on clinical trial operations for cancer indications in the United States. The FDA issued and since updated guidance to assist sponsors in assuring the safety of trial participants, maintaining compliance with Good Clinical Practice (GCP) and minimizing risks to trial integrity. Clinical trial sites have implemented institution-specific measures securing the safety of patients and staff to ensure the integrity of the trials in the face of the ongoing pandemic. All three studies have since been initiated despite the pandemic challenges; however, the evolving COVID-19 pandemic has impacted the pace of enrollment in clinical trials in general and we may be negatively affected with our trials. COVID-19 related travel and other restrictions may also impact the potential for on-site monitoring visiting and audits and inspections by us, third parties, and regulators. There may be shortages of site personnel and equipment necessary for the timely completion of our trials. We are providing support to address these challenges, but these mitigation measures may not overcome the obstacles that the pandemic has wrought which continue to impede progress of clinical trials.

Index

Although there is uncertainty related to the anticipated impact of the COVID-19 pandemic on our future results, we believe our current cash reserves, leave us well-positioned to manage our business through this crisis as it continues to unfold. However, the impacts of the COVID-19 pandemic are broad-reaching and continuing and the financial impacts associated with the COVID-19 pandemic are still uncertain.

Despite the economic uncertainty resulting from the COVID-19 pandemic, we intend to continue to focus on the development of our product candidates and we have expanded our infectious disease pipeline since the pandemic brought renewed resources and interest in technologies such as the Versamune® platform in the context of research and development in prevention of COVID-19. We are working with a consortium of partners in Brazil to develop PDS0203; a vaccine for the prevention of COVID-19. This consortium received a commitment from the Secretary for Research and Scientific Training of The Ministry of Science, Technology and Innovation of Brazil to fund up to approximately US$60 million to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil.

Note 2 – Summary of Significant Accounting Policies

(A)	Unaudited interim financial statements:

The interim balance sheet at March 31, 2021, the statements of operations and comprehensive loss and changes in stockholders’ equity for the three months ended March 31, 2021 and 2020, and cash flows for the three months ended March 31, 2021 and 2020 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The balance sheet as of December 31, 2020 included herein was derived from the audited condensed consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020, filed by the Company with the SEC in its Annual Report on Form 10-K on March 18, 2021.

(B)	Use of estimates:

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates.

(C)	Significant risks and uncertainties:

The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its products, the Company’s ability to preserve its cash resources, the Company’s review of strategic alternatives, the Company’s ability to add product candidates to its pipeline, the Company’s intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the Company’s ability to raise capital, and the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic.

The Company currently has no commercially approved products. As such, there can be no assurance that the Company’s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.

Index

(D)	Cash equivalents and concentration of cash balance:

The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.

(E)	Research and development:

Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on behalf of the Company.

Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.

(F)	Patent costs:

The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.

(G)	Stock-based compensation:

The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest rate and dividend yield. While the risk-free interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.

In lieu of higher cash compensation, the Company has granted non-employee options to consultants and expensed $344 and $0 during the three months ended March 31, 2021 and 2020, respectively.

(H)	Net income (loss) per common share:

Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the periods. For the periods presented, the common shares underlying the preferred stock, common stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.

The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:

	As of March 31,
	2021		2020
Stock options to purchase Common Stock		1,899,193		1,413,073
Warrants to purchase Common Stock		197,518		197,518
Total		2,096,711		1,610,591

Index

Note 3 – Liquidity

As of March 31, 2021, the Company had $25.0 million of cash and cash equivalents. The Company’s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change to the Company’s outstanding accounts payable and accrued expenses.

On July 29, 2019, we entered into a common stock purchase agreement, or the Aspire Purchase Agreement, with Aspire Capital pursuant to which, we have the right, in our sole discretion, to present Aspire Capital Fund, LLC, or Aspire Capital, with a purchase notice, directing Aspire Capital (as principal) to purchase up to 100,000 shares of our common stock per business day, in an aggregate amount of up to $20.0 million of our common stock, or the Purchased Shares, over the term of the Aspire Purchase Agreement. We may sell an aggregate of 1,034,979 shares of our common stock (which represented 19.99% of our outstanding shares of common stock on the date of the Aspire Purchase Agreement) without stockholder approval. We may sell additional shares of our common stock above the 19.99% limit provided that (i) we obtain stockholder approval or (ii) stockholder approval has not been obtained at any time the 1,034,979 share limitation is reached and at all times thereafter the average price paid for all shares issued under the Aspire Purchase Agreement, is equal to or greater than $5.76, which was the consolidated closing bid price of our common stock on July 26, 2019. The minimum price at which we can sell shares under the Aspire Purchase Agreement is $0.50. On July 29, 2019, we issued 100,654 shares of our common stock to Aspire Capital, as consideration for entering into the Aspire Purchase Agreement, which we refer to as the Commitment Shares. We recorded the fair value of the shares at July 29, 2019 of $603,924 as an expense in the third quarter of 2019. Concurrently with the Aspire Purchase Agreement, we entered into a registration rights agreement with Aspire Capital, or the Registration Rights Agreement. In accordance with the Registration Rights Agreement, on August 20, 2019 we filed a Registration Statement on Form S-1 (File No. 333-232988) to cover the resale of the Commitment Shares and any Purchased Shares issuable to Aspire Capital under the Aspire Purchase Agreement. There is market uncertainty regarding the utilization of financing associated from the Aspire Purchase Agreement. As of March 31, 2021, no Purchase Shares have been sold to Aspire Capital under the Aspire Purchase Agreement.

In February 2020, we completed an underwritten public offering, in which we sold 10,000,000 shares of common stock at a public offering price of $1.30 per share. The shares sold included 769,230 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $13 million and net proceeds of approximately $11.9 million after deducting underwriting discounts and commissions.

In July 2020, we filed a shelf registration statement, or the 2020 Shelf Registration Statement, with the SEC, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, which we refer to collectively as the Shelf Securities, up to an aggregate amount of $100 million. The 2020 Shelf Registration Statement was declared effective on July 31, 2020. On August 13, 2020, the Company sold 6,900,000 shares of its common stock at a public offering price of $2.75 per share pursuant to the 2020 Shelf Registration Statement, which includes 900,000 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $19.0 million and net proceeds of approximately $17.1 million, after deducting underwriting discounts and offering expenses. Approximately $81,000,000 of Shelf Securities remain available for future sale under the 2020 Shelf Registration Statement.

Our primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Our budgeted cash requirements in 2021 and beyond include expenses related to continuing development and clinical studies. Based on our available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, we believe there are sufficient funds to continue operations and research and development programs for at least 12 months from the date of this report.

Index

We plan to continue to fund our operations and capital funding needs through equity and/or debt financings. However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders. We may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market immunotherapies that we would otherwise prefer to develop and market ourselves. Any of these actions could harm our business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect its ability to operate as a going concern.

Note 4 – Fair Value of Financial Instruments

There were no transfers among Levels 1, 2, or 3 during 2021 or 2020.

	Fair Value Measurements at Reporting Date Using
	Total		Quoted Prices in Active Markets (Level 1)		Quoted Prices in Inactive Markets (Level 2)		Significant Unobservable Inputs (Level 3)
As of March 31, 2021: (unaudited)
Cash and cash equivalents	$	25,037,374	$	25,037,374	$	–	$	–

As of December 31, 2020
Cash and cash equivalents	$	28,839,565	$	28,839,565	$	–	$	–

Note 5 – Leases

On July 8, 2019, the Company entered into a lease termination agreement for its office space located at 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 effective August 31, 2019 (the “Lease Termination Agreement”). Pursuant to the Lease Termination Agreement, the Company was required to pay 50 percent of the remaining lease payments of $665,802 over three installments on September 1, 2019, December 1, 2019, and March 1, 2020, which was recorded as lease termination costs in the third quarter of 2019. The Company entered into a temporary month-to-month lease as of September 1, 2019 for office space located at 830 Morris Turnpike, Short Hills, NJ 07078 until the Company entered into a new lease for permanent office space. This lease was terminated on May 31, 2020.

Effective March 5, 2020, the Company entered into a sublease for approximately 11,200 square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 and will continue for a term of forty (40) months with an option to renew through October 31, 2027. As of March 31, 2021 there are twenty-nine (29) months remaining in the lease term. Upon inception of the lease, the Company recognized approximately $0.7 million of a ROU asset and operating lease liabilities. The discount rate used to measure the operating lease liability as of May 1, 2020 was 9.15%. Throughout the period described above the Company has maintained, and continues to maintain, a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.

Supplemental cash flow information related to operating leases is as follows:

	As of March 31,
	2021		2020
Cash paid for operating lease liabilities	$	42,057	$	-
Right-of use assets recorded in exchange for lease obligations	$	-	$	-

Index

Maturity of the Company’s operating lease liability is as follows:

Year ended December 31,
2021 (remaining nine months)	$	128,779
2022		295,346
2023		239,469
2024		-
2025 and after		-
Total future minimum lease payments		663,594
Less inputed interest		(81,649	)
	$	581,945

Note 6 – Accrued Expenses

Accrued expenses and other liabilities consist of the following:

	As of March 31, 2021		As of December 31, 2020
Accrued research and development costs	$	23,900	$	204,780
Accrued professional fees		320,266		219,822
Accrued compensation		1,510,629		1,310,720
Total	$	1,854,795	$	1,735,322

Note 7 – Stock-Based Compensation

The Company has three equity compensation plans: the 2009 Stock Option Plan, 2014 Equity Incentive Plan and the 2018 Stock Incentive Plan (the “Plans”).

In 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (“RSUs”), subject to increases as hereafter described (the “Plan Limit”). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to 826,292 shares.

In 2018, the Company’s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards.

Pursuant to the terms of the Plans, ISOs have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four year term and NQs generally vest over one to five year terms. Unless terminated by the Board, the Plans shall continue to remain effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding. As of March 31, 2021, there were 190,799 shares available for grant under the 2018 Stock Incentive Plan.

On June 17, 2019, the Board adopted the 2019 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan was recommended for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Index

On December 9, 2020, the Company amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from 200,000 shares to 500,000 shares. The 2019 Inducement Plan will be administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the 2019 Inducement Plan may only be made to an employee who has not previously been an employee or member of the Board (or any parent or subsidiary of the Company), or following a bona fide period of non-employment by the Company (or a parent or subsidiary of the Company), if he or she is granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. As March 31, 2021, there were 221,200 shares available for grant under the 2019 Inducement Plan.

The Company’s stock-based compensation expense was recognized in operating expense as follows:

	Three Months Ended March 31,
	2021		2020
	(unaudited)
Stock-Based Compensation
Research and development	$	60,385	$	52,684
General and administrative		197,236		72,308
Total	$	257,622	$	124,992

The fair value of options and warrants granted during the three months ended March 31, 2021 was estimated using the Black-Scholes option valuation model utilizing the following assumptions:

	Three Months Ended March 31,
	2021			2020
	Weighted Average			Weighted Average
	(unaudited)
Volatility		100.38	%		92.56	%
Risk-Free Interest Rate		0.35	%		1.56	%
Expected Term in Years		5.82			6.01
Dividend Rate		0.00	%		0.00	%
Fair Value of Option on Grant Date	$	1.73		$	0.99

The following table summarizes the number of options outstanding and the weighted average exercise price:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Options outstanding at December 31, 2020		1,650,897		$	11.87
Granted		267,800			2.32
Exercised		–			–
Forfeited		(19,500	)		23.87
Expired		–			–
Options outstanding at March 31, 2021		1,899,197		$	10.40		7.2	$	1,654,588
Vested and expected to vest at March 31, 2021		1,899,197		$	10.40		7.2	$	1,654,588
Exercisable at March 31, 2021		1,167,963		$	15.10		5.52	$	157,569

At March 31, 2021 there was approximately $1,483,195 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 3 years.

Index

Note 8 – Income Taxes

In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for 2021 and there will be no current income tax expense. Additionally, there was a full valuation allowance against the net deferred tax assets as of March 31, 2021 and December 31, 2020. As such, the Company recorded no income tax benefit due to realization uncertainties.

The Company’s U.S. statutory rate is 21%. The primary factor impacting the effective tax rate for the three months ended March 31, 2021 is the anticipated full year operating loss which will require full valuation allowances against any associated net deferred tax assets.

Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of March 31, 2021, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the three months ended March 31, 2021 and for the year ended December 31, 2020.

Note 9 – Commitments and Contingencies

Rent

For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three months ended March 31, 2021 and 2020, rent was $36,017 and $58,641 respectively.

Note 10 – Retirement Plan

The Company has a 401(k) defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $35,747 and $9,800 for the three months ended March 31, 2021 and 2020, respectively.

Note 11– Subsequent Events

Subsequent events have been evaluated through the date these financial statements were issued.

Index

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report”) and with the audited financial statements and notes thereto of the Company as of and for the year ended December 31, 2020 on Form 10-K, filed with the Securities and Exchange Commission, or SEC, on March 18, 2021.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” below. In light of these risks, uncertainties and assumptions, actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements in this Quarterly Report and you should not place undue reliance on these forward-looking statements.

These forward-looking statements may include, but are not limited to, statements about:

●

the accuracy of estimates of our expenses, future revenue, capital requirements and our needs for additional financing;

●

our ability to obtain funding for our operations in the event we determine the need to raise additional capital;

●

our ability to retain key management personnel;

●

the accuracy of our estimates regarding expenses, future revenues and capital requirements;

●

our ability to maintain our listing on the Nasdaq Stock Market;

●

regulatory developments in the United States and foreign countries;

●

unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19;

●

our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”); and

●

other risks and uncertainties, including those listed under Part II, Item 1A. Risk Factors.

Any forward-looking statements in this Quarterly Report reflect our views and assumptions only as of the date that this report is signed with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Index

Company Overview

We are a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapy and infectious disease vaccine candidates designed to overcome the limitations of current immunotherapy technologies. Our Versamune^® technology is a proprietary T-cell activating platform designed to train the immune system to better attack and destroy disease. When paired with an antigen (which is a disease-related protein that is recognizable by the immune system) Versamune^® induces, in vivo, large quantities of high-quality, highly potent polyfunctional CD8+ killer T-cells, a specific sub-type of CD8+ killer T-cell that is more effective at killing infected or target cells.

We believe that the Versamune® platform has the potential to become an industry-leading immuno-oncology technology and is currently being applied to the development of a robust pipeline of valuable “new-generation, multi-functional” immunotherapies, both as single agents and as part of combination therapies with other leading immuno-oncology technologies. We believe our product candidates are of interest for potential combination therapies in relation to Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers in advanced cancer or as monotherapies in early-stage disease.

It is well documented that the most critical attribute of an effective cancer immunotherapy is the induction of high levels of active antigen-specific CD8+ (killer) T-cells. Priming adequate levels of active CD8+ T-cells in-vivo continues to be a major obstacle facing immunotherapy. PDS0101 in its first human clinical trial provided data supporting the earlier promising preclinical study results and demonstrated the unique in-vivo induction of high levels of active HPV-specific CD8+ T-cells in humans.

PDS0101 in Combination with KEYTRUDA^® Clinical Trial:

In November 2020, our VERSATILE-002 Phase 2 clinical trial evaluating the combination of PDS0101 (Versamune^®with multiple HPV16 antigens) in combination with Merck’s anti-PD-1 therapy, KEYTRUDA^® (pembrolizumab) for first-line treatment of recurrent/ metastatic head and neck cancer opened and is actively recruiting patients. The clinical trial will evaluate the efficacy and safety of this therapeutic combination as a first-line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection. In June 2019, the FDA approved using KEYTRUDA^® in combination with platinum and fluorouracil (FU) for all patients for first line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma, or HNSCC, and as a single agent for patients whose tumors express PD-L1 as determined by an FDA-approved test.

In this sponsored trial, patients whose cancer has returned or spread following initial treatment, will be able to avoid chemotherapy and take this combination of two immuno-therapy drugs. Enrolling patients with more functional immune systems that have not been compromised by extensive chemotherapy may allow improved efficacy of the combination. Patients in the study will receive a total of 5 cycles of combination therapy in the context of standard of care KEYTRUDA™ therapy administered every three weeks until disease progression. The primary endpoint of VERSATILE-002 is the objective response rate – or ORR – at nine months following initiation of treatment. There will be a lead-in cohort of 12 patients to assess the safety of the combination, and a formal planned interim analysis evaluating response to treatment in the first 38 patients. Sites have implemented institution-specific measures securing the safety of patients and staff to ensure the integrity of the study in the face of the ongoing pandemic. The study’s Lead Principal Investigator is Dr. Jared Weiss, who serves as the section chief of Thoracic and Head and Neck/Neck Oncology at the University of North Carolina School of Medicine Lineberger Comprehensive Cancer Care Center. This trial is actively recruiting patients.

PDS0101 in Combination with Bintrafusp alfa (M7824) and NHS-IL12 Clinical Trial:

In June 2020, the first patient was dosed under a PDS0101 Cooperative Research and Development Agreement, which we refer to as the CRADA, in a National Cancer Institute, or NCI, led Phase 2 clinical study evaluating PDS0101, NHS-IL12, and M7824, owned by EMD Serono (Merck KGaA).

On April 28, 2021 we announced that initial efficacy and safety data from this study was accepted for oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in early June. Preclinical study results arising from this CRADA were published in the Journal for ImmunoTherapy of Cancer, Immunomodulation to enhance the efficacy of and HPV therapeutic vaccine (Journal for ImmunoTherapy of Cancer 2020;8:e000612. doi:10.1136/ jitc-2020-000612), indicating that PDS0101 generated both HPV-specific T-cells and an associated antitumor response when used as a monotherapy. When PDS0101 was combined with two other novel clinical-stage anti-cancer agents, Bintrafusp alfa (M7824) and NHS-IL12 preclinical data suggested that all three therapeutic agents worked synergistically to provide enhanced tumor T-cell response and subsequent tumor regression and when compared to any of the agents alone or 2-component combinations. If this preclinical data is successfully confirmed in the ongoing Phase 2 trial, this triple combination could form the basis of a unique platform providing improved cancer treatments across multiple cancers.

Index

This investigator-led study has achieved its initial safety benchmark – meaning that not more than 1 dose-limiting toxicity was observed in the first 6 patients who received the combination. In February 2021, we announced that this trial achieved its preliminary objective response target in patients naïve to checkpoint inhibitors. The trial is progressing to full enrollment of approximately 20 patients in this group. In addition, the trial was amended to allow enrollment of a separate cohort of checkpoint inhibitor-refractory patients, or patients who have received prior treatment with checkpoint inhibitors, for assessment of safety and activity of the triple combination. Preliminary efficacy assessment of the triple combination in this added group of 20 checkpoint inhibitor refractory patients is ongoing.

PDS0101 in Combination with Chemo-Radiotherapy Clinical Trial:

In October 2020, a third PDS0101 Phase 2 clinical trial was initiated with The University of Texas MD Anderson Cancer Center and is actively recruiting patients. This clinical trial is investigating the safety and anti-tumor efficacy of PDS0101 in combination with standard-of-care chemo-radiotherapy, or CRT, and their correlation with critical immunological biomarkers in patients with locally advanced cervical cancer. PDS believes that Versamune^®’s strong T-cell induction has the potential to meaningfully enhance efficacy of the current standard of care CRT treatment in this indication.

Other Versamune^®Products Under Development:

PDS0102 – Versamune^® + TARP antigens

The TARP antigen is over-expressed in acute myelogenous leukemia (AML), prostate and breast cancers. In the U.S. 450,000 patients are projected to be diagnosed with prostate or breast cancer this year. Approximately 90% of prostate cancers and 50% of breast cancers overexpress the TARP tumor antigen. In the U.S. 19,900 patients are projected to be diagnosed with AML this year. 100% of AML overexpress the TARP tumor antigen. In a human clinical study, the National Cancer Institute demonstrated that its proprietary TARP antigens were effectively recognized by the immune system in prostate cancer patients with PSA biochemical recurrence leading to a notable reduction in tumor growth rate. In preclinical studies, a dramatically enhanced TARP-specific killer T-cell response was observed when our designed TARP antigens were combined with Versamune® (PDS0102). Preclinical development is ongoing.

PDS0103 – Versamune^® + MUC-1 antigens

In April 2020, the PDS-NCI CRADA was expanded beyond PDS0101 to include clinical and preclinical development of PDS0103. PDS0103 is an investigational immunotherapy owned by us and designed to treat cancers associated with the mucin-1, or MUC-1, oncogenic protein. PDS0103 combines Versamune^® with novel highly immunogenic agonist epitopes of MUC-1 developed by the NCI and licensed by PDS. MUC1 is highly expressed in several types of cancer and has been shown to be associated with drug resistance and poor disease prognosis in breast, colorectal, lung and ovarian cancers, for which PDS0103 is being developed. In preclinical studies, and similarly to PDS0101, PDS0103 demonstrated the ability to generate powerful MUC-1-specific CD8 killer T-cells. PDS0103 is currently in late preclinical development.

PDS0104 – Versamune^® + TRP-2 and melanoma antigens

The rates of melanoma have been rising rapidly over the past few decades and approximately 96,480 new melanomas will be diagnosed this year alone. More than 7,000 of these will prove fatal. PDS0104 combines Versamune ® with various melanoma antigens including the Tyrosinase-related protein 2 (TRP2) which is highly expressed in melanoma. PDS0104 has been demonstrated in pre-clinical animal models of aggressive melanoma to have unique and significant anti-tumor activity as a monotherapy and has also demonstrated strong anti-tumor synergy in combination with checkpoint inhibitors. Preclinical development is ongoing.

Infectious Diseases

Our focus remains on developing our oncology products and progressing clinical trials described above, however we are also developing preventative vaccines to address several infectious diseases. Based on the key characteristics of Versamune^® we are progressing preclinical development of PDS0202, a universal influenza vaccine candidate, which combines Versamune^® with novel influenza vaccine antigens. PDS0202 pre-clinical development is being supported by an agreement with the National Institute of Allergy and Infectious Diseases Collaborative Influenza Vaccine Innovation Centers, or CIVICs, program, with a goal of progressing into a human clinical trial.

PDS0203 is being designed with the goal to potentially provide long-term and broad protection against infection from COVID-19 and its potential mutations. This second generation COVID-19 vaccine is based on the understood potential of Versamune^® to prime the immune system to generate both antibodies for near term protection and T-cell responses for long term protection against pathogens. We are jointly developing PDS0203 under a collaboration agreement with Farmacore.

Index

On March 11, 2021, we announced that the COVID-19 vaccine consortium consisting of PDS, Farmacore Biotechnology and Blanver Farmoquímica, received a commitment from the Secretary for Research and Scientific Training of The Ministry of Science, Technology and Innovation of Brazil (“MCTI”) to fund up to approximately US$60 million to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil. We are advised that MCTI intends to make a portion of the funding available, upon authorization by the Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (Anvisa) to initiate a combined Phase 1/2 clinical trial in Brazil. The majority of the capital provided by MCTI will fund the manufacturing process scale up, production and the Phase 3 trial, pending the results of the Phase 1/2 trial. All funding is contingent on the availability of financial resources within the MCTI, understanding that the public health response and political situation in Brazil is constantly evolving.

The pre-Investigational Medicinal Product Dossier, or “pre-IMPD” package for the Phase 1/2 trial is currently under review by Anvisa and the trial is anticipated to begin by the end of this year. The majority of the capital provided by MCTI will fund the manufacturing process scale up, production and the Phase 3 trial, pending the results of the Phase 1/2 trial. The Phase 1 and 2 trials, which will be run together, are anticipated to enroll approximately 360 patients and will assess the safety and efficacy of the vaccine as well as both the antibody and killer T-cell responses induced by the vaccine to the novel coronavirus. The clinical trials are planned to be conducted in Brazil.

As the license holder of PDS0203 in Latin America, Farmacore Biotechnology will continue to lead the regulatory and clinical trial efforts in Brazil and has selected a top clinical research organization, to conduct clinical trials in Brazil. We will continue to contribute scientific expertise and operational support. Blanver Farmoquímica will manufacture, promote, distribute, and commercialize the Versamune®-based COVID-19 vaccine in Latin America.

In December 2019, we entered into an Amended and Restated Material Transfer Agreement (MTA) with Farmacore to develop a novel tuberculosis, or TB, immunotherapy based on a combination of Farmacore’s proprietary TB antigens with Versamune®. In preliminary evaluations, our Versamune®-based TB product, PDS0201, demonstrated highly promising TB-specific T-cell induction in-vivo. Under the Farmacore MTA, we will undertake product development and Farmacore will conduct in-vivo preclinical studies to evaluate product efficacy.

We continue to primarily devote the majority of our resources and attention on the clinical oncology assets and execution of our oncology programs. Our current pipeline of Versamune®-based therapies is as follows:

From the Company’s inception, it has devoted substantially all of its efforts to drug development, business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital. We currently operate the existing business of Private PDS (as defined below) as a publicly traded company under the name PDS Biotechnology Corporation. We were incorporated as Edge Therapeutics, Inc., or Edge, on January 22, 2009. On March 15, 2019, privately held PDS Biotechnology Corporation, or Private PDS, completed a reverse merger, or the Merger, with Edge, pursuant to which Private PDS survived as a wholly owned subsidiary of Edge. Under the terms of the Merger, Edge changed its name to PDS Biotechnology Corporation and Private PDS changed its name to PDS Biotechnology Corporation.

Index

We have never been profitable and have incurred net losses in each year since inception. Our net losses were $3.0 million, and $4.0 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, we had an accumulated deficit of $46.8 million. Substantially all of our net losses have resulted from costs incurred in connection with its research and development programs and from general and administrative costs associated with these operations.

As of March 31, 2021, we had $25.0 million in cash and cash equivalents.

Our future funding requirements will depend on many factors, including the following:

●

the timing and costs of our planned clinical trials;

●

the timing and costs of our planned preclinical studies of our Versamune® platform;

●

the outcome, timing and costs of seeking regulatory approvals;

●

the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may enter into;

●

the amount and timing of any payments we may be required to make in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or patent applications or other intellectual property rights; and

●

the extent to which we license or acquire other products and technologies.

KEY COMPONENTS OF OUR STATEMENT OF OPERATIONS

Revenue

We have not generated any revenues from commercial product sales and do not expect to generate any such revenue in the near future. We may generate revenue in the future from a combination of research and development payments, license fees and other upfront payments or milestone payments.

Research and Development Expenses

Research and development expenses include employee-related expenses, licensing fees to use certain technology in our research and development projects, costs of acquiring, developing and manufacturing clinical trial materials, as well as fees paid to consultants and various entities that perform certain research and testing on our behalf. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expenses. Costs incurred in connection with research and development activities are expensed as incurred.

We expect that our research and development expenses will increase significantly over the next several years as we advance our Versamune®-based immuno-oncology, or I-O, candidates into and through clinical trials, pursues regulatory approval of our injectable Versamune® candidates and prepare for a possible commercial launch, all of which will also require a significant investment in contract and internal manufacturing and inventory related costs.

The process of conducting human clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for our injectable I-O candidates. The probability of successful commercialization of our I-O candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.

Index

Results of Operations

The following table summarizes the results of our operations for the three months ended March 31, 2021 and 2020:

	Three Months Ended March 31,						Increase (Decrease)
	2021			2020			$ Amount			%
	(in thousands)
Operating expenses:
Research and development expenses	$	1,413		$	1,971		$	(559	)		(28	)%
General and administrative expenses		1,636			2,060			(424	)		(21	)%
Total operating expenses		3,049			4,031			(983	)		(24	)%
Loss from operations		(3,049	)		(4,031	)		983			(24	)%
Interest income, net		1			46			(45	)		(98	)%
Net loss and comprehensive loss	$	(3,048	)	$	(3,985	)	$	936			(23	)%

Research and Development Expenses

Research and development (R&D) expenses decreased to $1.4 million for the three months ended March 31, 2021 from $2.0 million for the three months ended March 31, 2020. The decrease of $0.6 million in 2021 was primarily attributable to a decrease of $0.3 million in professional services and $0.3 million in clinical studies.

General and Administrative Expenses

General and administrative expenses decreased to $1.6 million for the three months ended March 31, 2021 from $2.1 million for the three months ended March 31, 2020. The decrease of $0.5 million is primarily attributable to a decrease in professional services of $0.7 million which includes legal fees of $0.2 million, offset by an increase of $0.2 million in personnel costs.

Interest income

Interest income, net was $0.001 million during the three months ended March 31, 2021, an decrease of $0.045 million, as compared to $0.046 million during the three months ended March 31, 2020, due primarily to interest received on invested cash and cash equivalents.

Liquidity and Capital Resources

Index

In July 2020, we filed a shelf registration statement, or the 2020 Shelf Registration Statement, with the SEC, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, which we refer to collectively as the Shelf Securities, up to an aggregate amount of $100 million. The 2020 Shelf Registration Statement was declared effective on July 31, 2020. On August 13, 2020, we sold 6,900,000 shares of its common stock at a public offering price of $2.75 per share pursuant to the 2020 Shelf Registration Statement, which includes 900,000 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $19.0 million and net proceeds of approximately $17.1 million, after deducting underwriting discounts and offering expenses. Approximately $81,000,000 of Shelf Securities remain available for future sale under the 2020 Shelf Registration Statement.

Our operations have also been financed from cash of $29.1 million from the consummation of the Merger in March 2019. As of March 31, 2021, we had $25.0 million of cash and cash equivalents.

We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Our budgeted cash requirements in 2021 and beyond include expenses related to continuing development and clinical studies. Based on our available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, we believe there are sufficient funds to continue operations and research and development programs for at least 12 months from the date of this Quarterly Report on Form 10-Q.

We plan to continue to fund our operations and capital funding needs through equity and/or debt financings. However, we cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or our existing stockholders. We may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market immunotherapies that we would otherwise prefer to develop and market ourselves. Any of these actions could harm our business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect its ability to operate as a going concern.

Cash Flows

The following table shows a summary of our cash flows for each of the periods indicated (in thousands):

	Three Months Ended March 31,
	2021			2020
Net cash used in operating activities	$	(3,802	)	$	(3,164	)
Net cash provided by financing activities		–			12,040
Net increase (decrease) in cash and cash equivalents	$	(3,802	)	$	8,876

Index

Net Cash Used in Operating Activities

Net cash used in operating activities was $3.8 million and $3.2 million for the three months ended March 31, 2021and 2020, respectively. The increase in cash used in operating activities of $0.6 million was primarily due to the increase of prepaid expenses related to the Syneos CRO contract.

Net Cash Provided by Financing Activities

Net cash provided by financing activities for the three months ended March 31, 2020 was due to the receipt of net proceeds from the issuance of common stock of $12.0 million.

Operating Capital Requirements

To date, we have not generated any product revenue. We do not know when, or if, we will generate any product revenue and we do not expect to generate significant product revenue unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our tablet vaccine candidates, and begin to commercialize any approved vaccine candidates. We are subject to all of the risks incident to the development of new products, and may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. We expect to incur additional costs associated with operating as a public company and anticipate that we will need substantial additional funding in connection with our continuing operations.

We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report. Our budgeted cash requirements in 2021 and beyond include expenses related to continuing development and clinical studies. We believe that our existing cash and cash equivalents as of December 31, 2020 are sufficient to continue operations and research and development programs for at least the next 12 months from the date of this Quarterly Report. Until we can generate significant cash from our operations, we expect to continue to fund our operations with available financial resources. These financial resources may not be adequate to sustain our operations.

We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

●

the initiation, progress, timing, costs and results of our planned clinical trials;

●

the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic, on our business operations, financial condition, results of operations and cash flows;

●

the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities;

●

the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;

●

the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us now or in the future;

●

the effect of competing technological and market developments;

●

the cost of establishing sales, marketing and distribution capabilities in regions where we choose to commercialize our products on our own; and

●

the initiation, progress, timing and results of our commercialization of our product candidates, if approved, for commercial sale.

Please see the section titled “Risk Factors” in this Quarterly Report on Form 10-Q for additional risks associated with our operations.

Index

Contractual Obligations and Commitments

The following is a summary of our contractual obligations as of the date indicated:

As of March 31, 2021	Total		Less than One Year		1-3 Years		3-5 Years		More than 5 Years
Operating lease obligations	$	581,945	$	123,654	$	458,291	$	–	$	–
Total contractual obligations	$	581,945	$	123,654	$	458,291	$	–	$	–

Purchase Commitments

We have no material non-cancelable purchase commitments with service providers as we have generally contracted on a cancelable, purchase order basis.

Critical Accounting Polices and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies and estimates during the three months ended March 31, 2021 from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020.

Impact of the CARES Act

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted and signed into law, and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among other things, includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act, including, permitting net operating losses, or NOLs, carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act provides other reliefs and stimulus measures. We have evaluated the impact of the CARES Act, and do not expect that any provision of the CARES Act would result in a material cash benefit to us or have a material impact on our financial statements or internal controls over financial reporting.

Operations and Liquidity

While the potential economic impact brought by and over the duration of the COVID-19 pandemic may be difficult to assess or predict, the COVID-19 pandemic has resulted in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition, a recession or market volatility resulting from the COVID-19 pandemic could affect our business. We have taken proactive, aggressive action throughout the COVID-19 pandemic to protect the health and safety of our employees and expect to continue to implement these measures until we determine that the COVID-19 pandemic is adequately contained for purposes of our business. We may take further actions as government authorities require or recommend or as we determine to be in the best interests of our employees. Given the nature and type of our short-term investments, we do not believe that the COVID-19 pandemic will have a material impact on our current investment liquidity.

Index

Outlook and Impact of COVID-19 on our Business

Despite the economic uncertainty resulting from the COVID-19 pandemic, we intend to continue to focus on the development of our product candidates and we have expanded our infectious disease pipeline since the pandemic brought renewed resources and interest on technologies such as the Versamune® platform in the context of research and development in prevention of COVID-19. We are working with a consortium of partners in Brazil to develop PDS0203; a vaccine for the prevention of COVID-19. This consortium received a commitment from the Secretary for Research and Scientific Training of The Ministry of Science, Technology and Innovation of Brazil to fund up to approximately US$60 million to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Smaller Reporting Company

As of January 1, 2021, we are no longer an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. However, we remain a “smaller reporting company,” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We will cease to be a smaller reporting company if we have a non-affiliate public float in excess of $250 million and annual revenues in excess of $100 million, or a non-affiliate public float in excess of $700 million, determined on an annual basis. Even though we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company. As a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not smaller reporting companies. We expect to continue to take advantage of some or all of the available exemptions.

Index

ITEM 3:

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

The primary objectives of our investment activities are to ensure liquidity and to preserve principal, while at the same time maximizing the income we receive from our cash and marketable securities without significantly increasing risk. As of March 31, 2021, we had cash equivalents of $25.0 million that were held in a non-interest-bearing money operating account and an institutional U.S. Treasury money market fund. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, we do not believe that an immediate 100 basis point change in interest rates would have a material effect on the fair market value of our cash equivalents. To minimize the risk in the future, we intend to maintain our portfolio of cash equivalents and short-term investments in institutional market funds that are comprised of U.S. Treasury and Treasury backed repurchase agreements.

ITEM 4:

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934, or the Exchange Act, as of the end of the period covered by this report. Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation identified above that occurred during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Index

PART II.

OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

From time to time, PDS may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Litigation, regardless of the outcome, could have an adverse impact on PDS because of defense and settlement costs, diversion of management resources and other factors. PDS is not currently a party to any legal proceedings, the adverse outcome of which, in PDS’s management’s opinion, individually or in the aggregate, would have a material adverse effect on PDS’s results of operations or financial position.

ITEM 1A.

RISK FACTORS

There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, 2020. However, any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our unaudited interim condensed consolidated financial statements and accompanying notes, our Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 18, 2021, including our financial statements and related notes contained therein, and the additional information in the other reports we file with the Securities and Exchange Commission. These risks may result in material harm to our business and our financial condition and results of operations. In this event, the market price of our common stock may decline and you could lose part or all of your investment. Additional risks that we currently believe are immaterial may also impair our business operations. Our business, financial conditions and future prospects and the trading price of our common stock could be harmed as a result of any of these risks.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no unregistered sales of the Company’s equity securities during the three months ended March 31, 2021.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

Index

EXHIBIT INDEX

Exhibit Number		Exhibit Description
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 *		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

32.2 *		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith (unless otherwise noted as being furnished herewith)

Index

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PDS Biotechnology Corporation

May 13, 2021	By:	/s/ Frank Bedu-Addo
		Frank Bedu-Addo
		President and Chief Executive Officer (Principal Executive Officer)

May 13, 2021	By:	/s/ Seth Van Voorhees
		Seth Van Voorhees
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 brhc10024337_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Frank Bedu-Addo, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended March 31, 2021;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 13, 2021	/s/ Frank Bedu-Addo
	Frank Bedu-Addo
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 brhc10024337_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Seth Van Voorhees, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended March 31, 2021;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 13, 2021	/s/ Seth Van Voorhees
	Seth Van Voorhees
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 brhc10024337_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the “Company”), on Form 10-Q for the quarter ended March 31, 2021 (the “Report”), I, Frank Bedu-Addo, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:

(1)

the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 13, 2021	/s/ Frank Bedu-Addo
	Frank Bedu-Addo
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-32.2 5 brhc10024337_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the “Company”), on Form 10-Q for the quarter ended March 31, 2021 (the “Report”), I, Seth Van Voorhees, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:

(1)

the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 13, 2021	/s/ Seth Van Voorhees
	Seth Van Voorhees
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.INS 6 pdsb-20210331.xml XBRL INSTANCE DOCUMENT 0001472091 2021-01-01 2021-03-31 0001472091 2021-05-07 0001472091 2021-03-31 0001472091 2020-12-31 0001472091 2020-01-01 2020-03-31 0001472091 us-gaap:RetainedEarningsMember 2020-12-31 0001472091 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001472091 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001472091 us-gaap:CommonStockMember 2019-12-31 0001472091 2019-12-31 0001472091 us-gaap:RetainedEarningsMember 2019-12-31 0001472091 us-gaap:CommonStockMember 2020-12-31 0001472091 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001472091 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001472091 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001472091 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001472091 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001472091 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001472091 us-gaap:RetainedEarningsMember 2021-03-31 0001472091 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001472091 us-gaap:CommonStockMember 2021-03-31 0001472091 us-gaap:RetainedEarningsMember 2020-03-31 0001472091 us-gaap:CommonStockMember 2020-03-31 0001472091 2020-03-31 0001472091 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001472091 2019-03-15 2019-03-15 0001472091 pdsb:MinistryOfScienceTechnologyAndInnovationOfBrazilMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-01-01 2021-03-31 0001472091 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-03-31 0001472091 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-01-01 2020-03-31 0001472091 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001472091 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001472091 pdsb:QualifiedAndNonqualifiedStockOptionsMember 2021-01-01 2021-03-31 0001472091 pdsb:QualifiedAndNonqualifiedStockOptionsMember 2020-01-01 2020-03-31 0001472091 srt:MaximumMember 2019-07-29 0001472091 2019-07-29 0001472091 2019-07-26 0001472091 srt:MinimumMember 2019-07-26 0001472091 2019-07-29 2019-07-29 0001472091 2020-02-01 2020-02-29 0001472091 us-gaap:OverAllotmentOptionMember 2020-02-01 2020-02-29 0001472091 us-gaap:OverAllotmentOptionMember 2020-08-13 2020-08-13 0001472091 2020-08-13 2020-08-13 0001472091 2020-08-13 0001472091 2020-02-29 0001472091 2020-07-31 0001472091 2020-01-01 2020-12-31 0001472091 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001472091 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001472091 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001472091 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001472091 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001472091 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001472091 2019-07-08 0001472091 2020-05-01 0001472091 pdsb:EquityIncentivePlan2014Member 2019-03-31 0001472091 pdsb:EquityIncentivePlan2018Member 2018-12-31 0001472091 pdsb:EquityIncentivePlan2014Member 2014-12-31 0001472091 pdsb:EquityIncentivePlan2014Member 2014-01-01 2014-12-31 0001472091 srt:MaximumMember pdsb:IncentiveStockOptionsMember pdsb:EquityCompensationPlansMember 2021-01-01 2021-03-31 0001472091 pdsb:IncentiveStockOptionsMember pdsb:EquityCompensationPlansMember 2021-01-01 2021-03-31 0001472091 pdsb:NonqualifiedStockOptionsMember srt:MaximumMember pdsb:EquityCompensationPlansMember 2021-01-01 2021-03-31 0001472091 srt:MinimumMember pdsb:EquityCompensationPlansMember pdsb:NonqualifiedStockOptionsMember 2021-01-01 2021-03-31 0001472091 pdsb:EquityCompensationPlansMember 2021-01-01 2021-03-31 0001472091 pdsb:InducementPlan2019Member 2021-03-31 0001472091 pdsb:EquityIncentivePlan2018Member 2021-03-31 0001472091 pdsb:InducementPlan2019Member 2020-12-08 0001472091 pdsb:InducementPlan2019Member 2020-12-09 0001472091 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001472091 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001472091 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001472091 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001472091 pdsb:QualifiedAndNonqualifiedStockOptionsMember 2020-12-31 0001472091 pdsb:QualifiedAndNonqualifiedStockOptionsMember 2021-01-01 2021-03-31 0001472091 pdsb:QualifiedAndNonqualifiedStockOptionsMember 2021-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure pdsb:ClinicalTrial pdsb:Installment utr:sqft pdsb:Plan

11200

950598

1415224

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 6 – Accrued Expenses</div><div><br /></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-indent: 36pt;">Accrued expenses and other liabilities consist of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: middle; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">As of</div><div style="text-align: center; color: rgb(0, 0, 0);"><font style="font-family: &quot;">March 31</font><font style="font-family: &quot;">, 2021</font></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">As of</div><div style="text-align: center; color: rgb(0, 0, 0);"><font style="font-family: &quot;">December 31</font><font style="font-family: &quot;">, 2020</font></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; width: 76%; background-color: #CCEEFF;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued research and development costs</div></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>23,900</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>204,780</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued professional fees</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>320,266</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>219,822</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued compensation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><div>1,510,629</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><div>1,310,720</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>1,854,795</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>1,735,322</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr></table></div>

1854795

1735322

219822

320266

71200684

70907315

257622

124992

257622

124992

197236

124992

60385

257622

72308

52684

197518

1899193

1610591

2096711

1413073

30890379

27761665

30337230

27256888

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 2 – Summary of Significant Accounting Policies</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(A)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Unaudited interim financial statements:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The interim balance sheet at March 31, 2021, the statements of operations and comprehensive loss and changes in stockholders’ equity for the three months ended March 31, 2021 and 2020, and cash flows for the three months ended March 31, 2021 and 2020 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The balance sheet as of December 31, 2020 included herein was derived from the audited condensed consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020, filed by the Company with the SEC in its Annual Report on Form 10-K on March 18, 2021.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(B)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Use of estimates:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(C)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Significant risks and uncertainties:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its products, the Company’s ability to preserve its cash resources, the Company’s review of strategic alternatives, the Company’s ability to add product candidates to its pipeline, the Company’s intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the Company’s ability to raise capital, and the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company currently has no commercially approved products. As such, there can be no assurance that the Company’s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(D)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Cash equivalents and concentration of cash balance:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(E)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Research and development:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on behalf of the Company.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(F)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Patent costs:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(G)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Stock-based compensation:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest rate and dividend yield. While the risk-free interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">In lieu of higher cash compensation, the Company has granted non-employee options to consultants and expensed $344 and $0 during the three months ended March 31, 2021 and 2020, respectively.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(H)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Net income (loss) per common share:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the periods. For the periods presented, the common shares underlying the preferred stock, common stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><br /></td><td colspan="1" rowspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" rowspan="1" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">As of March 31,</div></td><td colspan="1" nowrap="nowrap" rowspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &amp; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &amp; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2021</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &amp; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2020</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: bottom; font-family: &amp; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock options to purchase Common Stock</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,899,193</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,413,073</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: bottom; font-family: &amp; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants to purchase Common Stock</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>197,518</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>197,518</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: bottom; font-family: &amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>2,096,711</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>1,610,591</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td></tr></table></div>

25037374

28839565

8876067

-3802191

28839565

25037374

12161739

28839565

25037374

21037806

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 9 – Commitments and Contingencies</div><div><br /></div><div style="text-align: justify;"><u>Rent</u></div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three months ended March 31, 2021 and 2020, rent was $36,017 and $58,641 respectively.</div></div>

200000

500000

0.00033

22278261

22261619

75000000

22261619

22278261

7346

-3985408

-3048618

9800

35747

3902

1860

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 7 – Stock-Based Compensation</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company has three equity compensation plans: the 2009 Stock Option Plan, 2014 Equity Incentive Plan and the 2018 Stock Incentive Plan (the “Plans”).</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">In 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (“RSUs”), subject to increases as hereafter described (the “Plan Limit”). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to 826,292 shares.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">In 2018, the Company’s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards.</div><div><br /></div><div style="text-align: justify; text-indent: 24.5pt; color: rgb(0, 0, 0);">Pursuant to the terms of the Plans, ISOs have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four year term and NQs generally vest over one to five year terms. Unless terminated by the Board, the Plans shall continue to remain effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding. As of March 31, 2021, there were 190,799 shares available for grant under the 2018 Stock Incentive Plan.</div><div><br /></div><div style="text-align: justify; text-indent: 24.5pt;">On June 17, 2019, the Board adopted the 2019 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan was recommended for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">On December 9, 2020, the Company amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from 200,000 shares to 500,000 shares. The 2019 Inducement Plan will be administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the 2019 Inducement Plan may only be made to an employee who has not previously been an employee or member of the Board (or any parent or subsidiary of the Company), or following a bona fide period of non-employment by the Company (or a parent or subsidiary of the Company), if he or she is granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. As March 31, 2021, there were 221,200 shares available for grant under the 2019 Inducement Plan.</div><div><br /></div><div style="text-indent: 36pt;">The Company’s stock-based compensation expense was recognized in operating expense as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Three Months Ended March 31,</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">2021</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">2020</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-align: center;">(unaudited)</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock-Based Compensation</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 76%; background-color: #CCEEFF;"><div><div style="text-indent: -7.2pt; margin-left: 16.2pt;">Research and development</div></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>60,385</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>52,684</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 16.2pt;">General and administrative</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>197,236</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>72,308</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>257,622</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>124,992</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The fair value of options and warrants granted during the three months ended March 31, 2021 was estimated using the Black-Scholes option valuation model utilizing the following assumptions:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Three Months Ended March 31,</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">2021</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">2020</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Weighted Average</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Weighted Average</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-align: center;">(unaudited)</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><div>100.38</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><div>92.56</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk-Free Interest Rate</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.35</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1.56</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected Term in Years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><div>5.82</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><div>6.01</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value of Option on Grant Date</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1.73<br /></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.99</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr></table><div><br /></div><div style="text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Number</div><div style="text-align: center; font-family: &quot;">of Shares</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Weighted</div><div style="text-align: center; font-family: &quot;">Average</div><div style="text-align: center; font-family: &quot;">Exercise Price</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Weighted Average</div><div style="text-align: center; font-family: &quot;">Remaining</div><div style="text-align: center; font-family: &quot;">Contractual</div><div style="text-align: center; font-family: &quot;">Life in Years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Aggregate</div><div style="text-align: center; font-family: &quot;">Intrinsic Value</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">Options outstanding at </font><font style="font-family: &quot;">December 31, 2020</font></div></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div>1,650,897</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div>11.87</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right;"><div>267,800</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right;"><div>2.32</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right;"><div>(19,500</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"><div>)</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right;"><div>23.87</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expired</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">Options outstanding at </font><font style="font-family: &quot;">March 31, 2021</font></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>1,899,197</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>10.40</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;"><div>7.2<br /></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;"><div>1,654,588</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">Vested and expected to vest at </font><font style="font-family: &quot;">March 31, 2021</font></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>1,899,197</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>10.40</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div>7.2<br /></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div>1,654,588</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">Exercisable at </font><font style="font-family: &quot;">March 31, 2021</font></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>1,167,963</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>15.10</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;"><div>5.52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;"><div>157,569</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">At March 31, 2021 there was approximately $1,483,195 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 3 years.</div></div>

-0.39

-0.14

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(H)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Net income (loss) per common share:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the periods. For the periods presented, the common shares underlying the preferred stock, common stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><br /></td><td colspan="1" rowspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" rowspan="1" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">As of March 31,</div></td><td colspan="1" nowrap="nowrap" rowspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &amp; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &amp; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2021</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &amp; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2020</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: bottom; font-family: &amp; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock options to purchase Common Stock</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,899,193</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,413,073</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: bottom; font-family: &amp; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants to purchase Common Stock</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>197,518</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>197,518</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: bottom; font-family: &amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>2,096,711</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>1,610,591</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td></tr></table></div>

-0.14

-0.39

0.21

1483195

P3Y

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 4 – Fair Value of Financial Instruments</div><div><br /></div><div style="text-indent: 36pt;">There were no transfers among Levels 1, 2, or 3 during 2021 or 2020.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="14" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Fair Value Measurements at Reporting Date Using</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Total</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Quoted Prices in</div><div style="text-align: center; font-family: &quot;">Active Markets</div><div style="text-align: center; font-family: &quot;">(Level 1)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Quoted Prices in</div><div style="text-align: center; font-family: &quot;">Inactive Markets</div><div style="text-align: center; font-family: &quot;">(Level 2)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Significant</div><div style="text-align: center; font-family: &quot;">Unobservable Inputs</div><div style="text-align: center; font-family: &quot;">(Level 3)</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">As of March 31, 2021: (unaudited)</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cash and cash equivalents</div></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>25,037,374</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>25,037,374</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 52%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">As of </font><font style="font-family: &quot;">December 31, 2020</font></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 52%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cash and cash equivalents</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>28,839,565</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>28,839,565</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="14" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Fair Value Measurements at Reporting Date Using</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Total</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Quoted Prices in</div><div style="text-align: center; font-family: &quot;">Active Markets</div><div style="text-align: center; font-family: &quot;">(Level 1)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Quoted Prices in</div><div style="text-align: center; font-family: &quot;">Inactive Markets</div><div style="text-align: center; font-family: &quot;">(Level 2)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Significant</div><div style="text-align: center; font-family: &quot;">Unobservable Inputs</div><div style="text-align: center; font-family: &quot;">(Level 3)</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">As of March 31, 2021: (unaudited)</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cash and cash equivalents</div></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>25,037,374</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>25,037,374</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 52%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">As of </font><font style="font-family: &quot;">December 31, 2020</font></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 52%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cash and cash equivalents</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>28,839,565</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>28,839,565</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr></table></div>

2060148

1636216

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 8 – Income Taxes</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for 2021 and there will be no current income tax expense.  Additionally, there was a full valuation allowance against the net deferred tax assets as of March 31, 2021 and December 31, 2020. As such, the Company recorded no income tax benefit due to realization uncertainties.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company’s U.S. statutory rate is 21%.  The primary factor impacting the effective tax rate for the three months ended March 31, 2021 is the anticipated full year operating loss which will require full valuation allowances against any associated net deferred tax assets.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of March 31, 2021, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.  The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the three months ended March 31, 2021 and for the year ended December 31, 2020.</div></div>

-228298

-464626

1358983

122551

119473

721849

570916

46419

655

603924

P40M

P29M

0.0915

81649

128779

663594

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; text-indent: 36pt;">Maturity of the Company’s operating lease liability is as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Year ended December 31,</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2021 (remaining nine months)</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>128,779</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2022</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>295,346</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2023</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>239,469</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2024</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2025 and after</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total future minimum lease payments</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>663,594</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Less inputed interest</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div>(81,649</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%; padding-bottom: 4px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>581,945</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 5 – Leases</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">On July 8, 2019, the Company entered into a lease termination agreement for its office space located at 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 effective August 31, 2019 (the “Lease Termination Agreement”). Pursuant to the Lease Termination Agreement, the Company was required to pay 50 percent of the remaining lease payments of $665,802 over three installments on September 1, 2019, December 1, 2019, and March 1, 2020, which was recorded as lease termination costs in the third quarter of 2019. The Company entered into a temporary month-to-month lease as of September 1, 2019 for office space located at 830 Morris Turnpike, Short Hills, NJ 07078 until the Company entered into a new lease for permanent office space. This lease was terminated on May 31, 2020.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Effective March 5, 2020, the Company entered into a sublease for approximately 11,200 square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 and will continue for a term of forty (40) months with an option to renew through October 31, 2027. As of March 31, 2021 there are twenty-nine (29) months remaining in the lease term. Upon inception of the lease, the Company recognized approximately $0.7 million of a ROU asset and operating lease liabilities. The discount rate used to measure the operating lease liability as of May 1, 2020 was 9.15%. Throughout the period described above the Company has maintained, and continues to maintain, a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Supplemental cash flow information related to operating leases is as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">As of March 31,</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2021</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2020</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash paid for operating lease liabilities</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>42,057</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &quot;">Right-of use assets recorded in exchange for lease obligations</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Maturity of the Company’s operating lease liability is as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Year ended December 31,</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2021 (remaining nine months)</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>128,779</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2022</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>295,346</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2023</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>239,469</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2024</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2025 and after</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total future minimum lease payments</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>663,594</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Less inputed interest</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div>(81,649</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 88%; padding-bottom: 4px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>581,945</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr></table></div>

239469

295346

36017

58641

30890379

27761665

3387338

3760803

2929047

3270450

60000000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 1 – Nature of Operations</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;"><div style="text-align: justify; font-family: 'Times New Roman','Times New Roman',serif; font-size: 10pt;">PDS Biotechnology Corporation, a Delaware corporation (the “Company” or “PDS”), is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines designed to overcome the well-established limitations of current immunotherapy technologies.  PDS owns Versamune<sup style="color: rgb(0, 0, 0); vertical-align: text-top; line-height: 1; font-size: smaller;">®</sup>, a proprietary T-cell activating platform designed to train the immune system to better attack and destroy disease. When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune<sup style="color: rgb(0, 0, 0); vertical-align: text-top; line-height: 1; font-size: smaller;">®</sup> has been shown to induce, <font style="font-style: italic;">in vivo,</font> large quantities of high-quality, highly potent polyfunctional CD8+ killer T-cells, a specific sub-type of CD8+ killer T-cell that is more effective at killing infected or target cells. Our immuno-oncology products can potentially be used as a component of combination products with other leading technologies to provide effective treatments across a range of cancer types. We believe our product candidates are of interest for potential in relation to Human Papillomavirus, or HPV,- associated cancers, melanoma, colorectal, lung, breast and prostate cancers or as monotherapies in early-stage disease.  PDS is working to expand its infectious disease pandemic development program, which includes novel vaccines for COVID-19 and universal influenza.</div></div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">From the Company’s inception, it has devoted substantially all of its efforts to drug development, business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">On March 15, 2019, the Company, then operating as Edge Therapeutics, Inc. (“Edge”), completed its reverse merger with privately held PDS Biotechnology Corporation (“Private PDS”), pursuant to and in accordance with the terms of the Agreement and Plan of Merger, dated as of November 23, 2018, as amended on January 24, 2019, by and among the Company, Echos Merger Sub, a wholly-owned subsidiary of the Company (“Merger Sub”), and Private PDS, whereby Private PDS merged with and into Merger Sub, with Private PDS surviving as the Company’s wholly-owned subsidiary (the “Merger”).<font style="font-style: italic;"> </font>In connection with and immediately following completion of the Merger, the Company effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) and changed its corporate name from Edge Therapeutics, Inc. to PDS Biotechnology Corporation, and Private PDS changed its name to PDS Operating Corporation.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">For accounting purposes, the Merger was treated as a “reverse acquisition” under generally accepted accounting principles in the United States (“U.S. GAAP”) and Private PDS is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Private PDS became the Company’s historical financial statements, and the historical financial statements of Private PDS are included in the comparative prior periods. As part of the Merger, the Company acquired all of Edge’s assets relating to current and future research and development.</div><div><br /></div><div style="text-align: justify; text-indent: 20pt;">In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a pandemic and on March 13 the President declared a national emergency in response to the pandemic. The full impact of the COVID-19 pandemic is unknown and rapidly evolving. The COVID-19 pandemic has and could continue to negatively affect the Company’s liquidity and operations.  To date, two of the three recently initiated PDS0101 clinical trials were delayed, specifically as a result of the adverse impact the COVID-19 pandemic has had on clinical trial operations for cancer indications in the United States. The FDA issued and since updated guidance to assist sponsors in assuring the safety of trial participants, maintaining compliance with Good Clinical Practice (GCP) and minimizing risks to trial integrity.  Clinical trial sites have implemented institution-specific measures securing the safety of patients and staff to ensure the integrity of the trials in the face of the ongoing pandemic. All three studies have since been initiated despite the pandemic challenges; however, the evolving COVID-19 pandemic has impacted the pace of enrollment in clinical trials in general and we may be negatively affected with our trials. COVID-19 related travel and other restrictions may also impact the potential for on-site monitoring visiting and audits and inspections by us, third parties, and regulators. There may be shortages of site personnel and equipment necessary for the timely completion of our trials. We are providing support to address these challenges, but these mitigation measures may not overcome the obstacles that the pandemic has wrought which continue to impede progress of clinical trials.</div><div style="text-align: justify; text-indent: 20pt;"><br /></div><div style="text-align: justify; text-indent: 36pt;">Although there is uncertainty related to the anticipated impact of the COVID-19 pandemic on our future results, we believe our current cash reserves, leave us well-positioned to manage our business through this crisis as it continues to unfold. However, the impacts of the COVID-19 pandemic are broad-reaching and continuing and the financial impacts associated with the COVID-19 pandemic are still uncertain.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Despite the economic uncertainty resulting from the COVID-19 pandemic, we intend to continue to focus on the development of our product candidates and we have expanded our infectious disease pipeline since the pandemic brought renewed resources and interest in technologies such as the Versamune® platform in the context of research and development in prevention of COVID-19.  We are working with a consortium of partners in Brazil to develop PDS0203; a vaccine for the prevention of COVID-19.  This consortium received a commitment from the Secretary for Research and Scientific Training of The Ministry of Science, Technology and Innovation of Brazil to fund up to approximately US$60 million to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil.</div></div>

-3802191

-3164394

-3048618

-3985408

-3048618

12040461

42057

700000

581945

458291

490353

119904

123654

3049273

4031827

547706

501194

700000

60257

-3049273

-4031827

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 10 – Retirement Plan</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company has a 401(k) defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $35,747 and $9,800 for the three months ended March 31, 2021 and 2020, respectively.</div></div>

1497665

2219514

70459

11970002

13000000

19000000

5443

3583

1413057

1971679

-43785085

-46833703

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 3 – Liquidity</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">As of March 31, 2021, the Company had $25.0 million of cash and cash equivalents. The Company’s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change to the Company’s outstanding accounts payable and accrued expenses.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">On July 29, 2019, we entered into a common stock purchase agreement, or the Aspire Purchase Agreement, with Aspire Capital pursuant to which, we have the right, in our sole discretion, to present Aspire Capital Fund, LLC, or Aspire Capital, with a purchase notice, directing Aspire Capital (as principal) to purchase up to 100,000 shares of our common stock per business day, in an aggregate amount of up to $20.0 million of our common stock, or the Purchased Shares, over the term of the Aspire Purchase Agreement. We may sell an aggregate of 1,034,979 shares of our common stock (which represented 19.99% of our outstanding shares of common stock on the date of the Aspire Purchase Agreement) without stockholder approval. We may sell additional shares of our common stock above the 19.99% limit provided that (i) we obtain stockholder approval or (ii) stockholder approval has not been obtained at any time the 1,034,979 share limitation is reached and at all times thereafter the average price paid for all shares issued under the Aspire Purchase Agreement, is equal to or greater than $5.76, which was the consolidated closing bid price of our common stock on July 26, 2019. The minimum price at which we can sell shares under the Aspire Purchase Agreement is $0.50. On July 29, 2019, we issued 100,654 shares of our common stock to Aspire Capital, as consideration for entering into the Aspire Purchase Agreement, which we refer to as the Commitment Shares. We recorded the fair value of the shares at July 29, 2019 of $603,924 as an expense in the third quarter of 2019. Concurrently with the Aspire Purchase Agreement, we entered into a registration rights agreement with Aspire Capital, or the Registration Rights Agreement. In accordance with the Registration Rights Agreement, on August 20, 2019 we filed a Registration Statement on Form S-1 (File No. 333-232988) to cover the resale of the Commitment Shares and any Purchased Shares issuable to Aspire Capital under the Aspire Purchase Agreement. There is market uncertainty regarding the utilization of financing associated from the Aspire Purchase Agreement. As of March 31, 2021, no Purchase Shares have been sold to Aspire Capital under the Aspire Purchase Agreement.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">In February 2020, we completed an underwritten public offering, in which we sold 10,000,000 shares of common stock at a public offering price of $1.30 per share. The shares sold included 769,230 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $13 million and net proceeds of approximately $11.9 million after deducting underwriting discounts and commissions.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">In July 2020, we filed a shelf registration statement, or the 2020 Shelf Registration Statement, with the SEC, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, which we refer to collectively as the Shelf Securities, up to an aggregate amount of $100 million. The 2020 Shelf Registration Statement was declared effective on July 31, 2020. On August 13, 2020, the Company sold 6,900,000 shares of its common stock at a public offering price of $2.75 per share pursuant to the 2020 Shelf Registration Statement, which includes 900,000 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $19.0 million and net proceeds of approximately $17.1 million, after deducting underwriting discounts and offering expenses. Approximately $81,000,000 of Shelf Securities remain available for future sale under the 2020 Shelf Registration Statement.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">Our primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q.  Our budgeted cash requirements in 2021 and beyond include expenses related to continuing development and clinical studies.  Based on our available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, we believe there are sufficient funds to continue operations and research and development programs for at least 12 months from the date of this report.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">We plan to continue to fund our operations and capital funding needs through equity and/or debt financings. However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders.  We may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market immunotherapies that we would otherwise prefer to develop and market ourselves. Any of these actions could harm our business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect its ability to operate as a going concern.</div></div>

P5Y6M7D

P10Y

P7Y2M12D

P5Y9M25D

P6Y0M4D

157569

P7Y2M12D

17100000

11900000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; text-indent: 36pt;">The fair value of options and warrants granted during the three months ended March 31, 2021 was estimated using the Black-Scholes option valuation model utilizing the following assumptions:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Three Months Ended March 31,</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">2021</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">2020</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Weighted Average</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Weighted Average</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-align: center;">(unaudited)</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Volatility</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><div>100.38</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><div>92.56</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk-Free Interest Rate</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.35</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1.56</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected Term in Years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><div>5.82</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><div>6.01</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend Rate</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair Value of Option on Grant Date</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1.73<br /></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.99</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Number</div><div style="text-align: center; font-family: &quot;">of Shares</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Weighted</div><div style="text-align: center; font-family: &quot;">Average</div><div style="text-align: center; font-family: &quot;">Exercise Price</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Weighted Average</div><div style="text-align: center; font-family: &quot;">Remaining</div><div style="text-align: center; font-family: &quot;">Contractual</div><div style="text-align: center; font-family: &quot;">Life in Years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">Aggregate</div><div style="text-align: center; font-family: &quot;">Intrinsic Value</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">Options outstanding at </font><font style="font-family: &quot;">December 31, 2020</font></div></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div>1,650,897</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div>11.87</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right;"><div>267,800</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right;"><div>2.32</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right;"><div>(19,500</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"><div>)</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right;"><div>23.87</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expired</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div>–</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">Options outstanding at </font><font style="font-family: &quot;">March 31, 2021</font></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>1,899,197</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>10.40</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;"><div>7.2<br /></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;"><div>1,654,588</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">Vested and expected to vest at </font><font style="font-family: &quot;">March 31, 2021</font></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>1,899,197</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>10.40</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div>7.2<br /></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div>1,654,588</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><font style="font-family: &quot;">Exercisable at </font><font style="font-family: &quot;">March 31, 2021</font></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>1,167,963</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>15.10</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;"><div>5.52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;"><div>157,569</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-indent: 36pt;">Accrued expenses and other liabilities consist of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: middle; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">As of</div><div style="text-align: center; color: rgb(0, 0, 0);"><font style="font-family: &quot;">March 31</font><font style="font-family: &quot;">, 2021</font></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: &quot;">As of</div><div style="text-align: center; color: rgb(0, 0, 0);"><font style="font-family: &quot;">December 31</font><font style="font-family: &quot;">, 2020</font></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; width: 76%; background-color: #CCEEFF;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued research and development costs</div></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>23,900</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>204,780</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued professional fees</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>320,266</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>219,822</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued compensation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><div>1,510,629</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"> </td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><div>1,310,720</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>1,854,795</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div>1,735,322</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; text-indent: 36pt;">The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><br /></td><td colspan="1" rowspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" rowspan="1" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">As of March 31,</div></td><td colspan="1" nowrap="nowrap" rowspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &amp; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &amp; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2021</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &amp; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2020</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: bottom; font-family: &amp; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock options to purchase Common Stock</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,899,193</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,413,073</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: bottom; font-family: &amp; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants to purchase Common Stock</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>197,518</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>197,518</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: bottom; font-family: &amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>2,096,711</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>1,610,591</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 36pt;">The Company’s stock-based compensation expense was recognized in operating expense as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">Three Months Ended March 31,</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">2021</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center;">2020</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot;"><div style="text-align: center;">(unaudited)</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; font-family: &quot;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock-Based Compensation</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 76%; background-color: #CCEEFF;"><div><div style="text-indent: -7.2pt; margin-left: 16.2pt;">Research and development</div></div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>60,385</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>52,684</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 16.2pt;">General and administrative</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>197,236</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div>72,308</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>257,622</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div>124,992</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"> </td></tr></table></div>

2.32

124992

257622

5.76

0.50

267800

23.87

P4Y

P5Y

P1Y

0.0000

0.9256

1.0038

0.99

1.73

221200

190799

826292

558071

91367

15.10

1167963

0.0156

0.0035

19500

1654588

1650897

1899197

11.87

10.40

1654588

1899197

10.40

5281237

22261619

15350445

22278261

2.75

1.30

16642

3968

9799

35747

9800

35747

10000000

769230

900000

6900000

3299

11970002

11966703

344

0.05

24374327

27129576

-43785085

40633670

70907315

1742

11697707

-28937705

7346

-46833703

52805601

7346

-32923113

5064

19887552

71200684

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note 11– Subsequent Events</div><div><br /></div><div style="text-indent: 36pt;">Subsequent events have been evaluated through the date these financial statements were issued.</div></div>

10314761

22263838

10314761

22263838

1310720

1510629

false --12-31 2021-03-31 NJ Yes Non-accelerated Filer PDS Biotechnology Corp 0001472091 22278261 2021 Q1 10-Q Yes false false true P10Y 3 0.04 <div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; font-weight: bold;">(C)</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Significant risks and uncertainties:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its products, the Company’s ability to preserve its cash resources, the Company’s review of strategic alternatives, the Company’s ability to add product candidates to its pipeline, the Company’s intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the Company’s ability to raise capital, and the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The Company currently has no commercially approved products. As such, there can be no assurance that the Company’s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.</div></div> 100000000 1034979 20000000 100654 0.1999 0 81000000 100000 65240 22 0 70459 70437 <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; text-indent: 36pt;">Supplemental cash flow information related to operating leases is as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">As of March 31,</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2021</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="1" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-family: &quot; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">2020</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-family: &quot; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash paid for operating lease liabilities</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>42,057</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &quot;">Right-of use assets recorded in exchange for lease obligations</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"><div>$</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; text-align: right; width: 9%;"><div>-</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="font-family: &quot; vertical-align: bottom; width: 1%;"> </td></tr></table></div> 0 -42057 0 204780 23900 0 0.5 3 665802 2 3 EX-101.SCH 7 pdsb-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Retirement Plan link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Nature of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Leases, Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 090502 - Disclosure - Leases, Supplemental Cash Flow Information Related to Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 090504 - Disclosure - Leases, Future Payments for Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 090506 - Disclosure - Leases, Future Payments for Operating Lease Liabilities (Details) CALC 01 link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Retirement Plan (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pdsb-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pdsb-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pdsb-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Area of office space under sub-lease Area of Real Estate Property Award Type [Axis] Summary of Significant Accounting Policies [Abstract] Accounts payable Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Total Accrued expenses Accrued Liabilities, Current Accrued professional fees Additional Paid-in Capital [Member] Additional paid-in capital Additional Paid in Capital Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Expense Antidilutive impact to EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] ASSETS Assets [Abstract] Total assets Assets Total current assets Assets, Current Current assets: Assets, Current [Abstract] Unaudited Interim Financial Statements Summary of Significant Accounting Policies Business Acquisition [Line Items] Liquidity [Abstract] Business Combination, Consideration Transferred [Abstract] Cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Supplemental Cash Flow Information Related to Operating Leases [Abstract] Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash Equivalents and Concentration of Cash Balance Cash and Cash Equivalents, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies [Abstract] Common stock reserved for issuance (in shares) Common Stock [Member] Common stock, par value (in dollars per share) Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock shares outstanding (in shares) Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2021 and December 31, 2020, 22,278,261 shares and 22,261,619 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Retirement Plan [Abstract] Comprehensive loss Current income tax expense 401(k) employer contribution Stock-based 401K company common match Depreciation expense Depreciation Stock-Based Compensation [Abstract] Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net Income (Loss) per Common Share [Abstract] Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Per share information: Net loss per share, basic (in dollars per share) Net Income (Loss) per Common Share Earnings Per Share, Policy [Policy Text Block] Net loss per share, diluted (in dollars per share) Federal statutory rate Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Unamortized Stock Compensation Expense [Abstract] Stock Options [Abstract] Share-based Payment Arrangement, Additional Disclosure [Abstract] Unamortized stock compensation expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Equity Component [Domain] Fair Value of Financial Instruments [Abstract] Fair Value, Net Asset (Liability) [Abstract] Transfers from Level 1 to Level 2 Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Transfers from Level 2 to Level 1 Fair Value, Assets, Level 2 to Level 1 Transfers, Amount Fair Value Transfers Between Levels [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Transfers into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Fair Value of Financial Instruments [Abstract] Transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value of Financial Instruments Fair Value of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Quoted Prices in Active Markets (Level 1) [Member] Quoted Prices in Inactive Markets (Level 2) [Member] Significant Unobservable Inputs (Level 3) [Member] Grantee Status [Axis] Grantee Status [Domain] General and administrative expenses General and Administrative Expense General and Administrative [Member] Income Statement Location [Axis] Income Taxes [Abstract] Income Statement Location [Domain] Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract] Income Taxes Accrued interest and penalties Income tax benefit Restructuring reserve Increase (Decrease) in Restructuring Reserve Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Stockholders' Equity [Roll Forward] Interest income Investment Income, Interest Issuance of common stock from equity transaction Term of sub-lease agreement Lessor, Operating Lease, Term of Contract Remaining lease term 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Discount rate used to measure operating lease liability Lessee, Operating Lease, Discount Rate Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2021 (remaining nine months) Leases [Abstract] Lessee, Operating Lease, Description [Abstract] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Future Payments for Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Leases 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Rent expense Leases [Abstract] LIABILITIES Liabilities [Abstract] Total liabilities and stockholders' equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Total Liabilities Liabilities Noncurrent liability: Liabilities, Noncurrent [Abstract] Total current liabilities Liabilities, Current Current liabilities: Nature of Operations [Abstract] Long-term Commitment (Excluding Unconditional Purchase Obligation) [Abstract] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment [Table] Category of Item Purchased [Axis] Committed funding to COVID-19 vaccine consortium Long-term Purchase Commitment, Amount Nature of Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net loss Net loss Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Over-Allotment Option [Member] Cash paid for operating lease liabilities Future Payments for Operating Lease Liabilities [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Operating lease liability Lease liability Operating Lease, Liability Operating lease obligation - long term Operating Lease, Liability, Noncurrent Operating lease obligation-short term Operating Lease, Liability, Current Total operating expenses Operating Expenses Right-of-use asset Operating lease right-to-use asset Operating expenses: Operating Expenses [Abstract] Operating lease expense Loss from operations Operating Income (Loss) Nature of Operations [Abstract] Other income Other Income and Expenses [Abstract] Accrued Expenses [Abstract] Retirement Plan Plan Name [Axis] Plan Name [Domain] Prepaid expenses and other Prepaid Expense and Other Assets, Current Proceeds from exercise of warrants Proceeds from issuance of shares Proceeds from issuance of common stock, net of issuance costs Property and equipment, net Property, Plant and Equipment, Net Right-of use assets recorded in exchange for lease obligations Research and development expenses Research and Development Expense Research and Development Research and Development Expense, Policy [Policy Text Block] Clinical Development and Commercialization of COVID-19 Vaccine [Member] Research and Development Arrangement [Member] Research and Development [Member] EX-101.PRE 11 pdsb-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 image00001.jpg begin 644 image00001.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 07, 2021
Cover [Abstract]
Entity Registrant Name	PDS Biotechnology Corp
Entity Central Index Key	0001472091
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Address, State or Province	NJ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,278,261

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 25,037,374	$ 28,839,565
Prepaid expenses and other	2,219,514	1,497,665
Total current assets	27,256,888	30,337,230
Property and equipment, net	3,583	5,443
Operating lease right-to-use asset	501,194	547,706
Total assets	27,761,665	30,890,379
Current liabilities:
Accounts payable	950,598	1,415,224
Accrued expenses	1,854,795	1,735,322
Operating lease obligation-short term	123,654	119,904
Total current liabilities	2,929,047	3,270,450
Noncurrent liability:
Operating lease obligation - long term	458,291	490,353
Total Liabilities	3,387,338	3,760,803
STOCKHOLDERS' EQUITY
Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2021 and December 31, 2020, 22,278,261 shares and 22,261,619 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	7,346	7,346
Additional paid-in capital	71,200,684	70,907,315
Accumulated deficit	(46,833,703)	(43,785,085)
Total stockholders' equity	24,374,327	27,129,576
Total liabilities and stockholders' equity	$ 27,761,665	$ 30,890,379

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
STOCKHOLDERS' EQUITY
Common stock, par value (in dollars per share)	$ 0.00033	$ 0.00033
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	22,278,261	22,261,619
Common stock shares outstanding (in shares)	22,278,261	22,261,619

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development expenses	$ 1,413,057	$ 1,971,679
General and administrative expenses	1,636,216	2,060,148
Total operating expenses	3,049,273	4,031,827
Loss from operations	(3,049,273)	(4,031,827)
Other income
Interest income	655	46,419
Net loss	(3,048,618)	(3,985,408)
Comprehensive loss	$ (3,048,618)	$ (3,985,408)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.14)	$ (0.39)
Net loss per share, diluted (in dollars per share)	$ (0.14)	$ (0.39)
Weighted average common shares outstanding, basic (in shares)	22,263,838	10,314,761
Weighted average common shares outstanding, diluted (in shares)	22,263,838	10,314,761

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2019	$ 1,742	$ 40,633,670	$ (28,937,705)	$ 11,697,707
Balance (in shares) at Dec. 31, 2019	5,281,237
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	124,992	0	124,992
Issuance of common stock, net of issuance costs	$ 3,299	11,966,703	0	11,970,002
Issuance of common stock, net of issuance costs (in shares)	10,000,000
Issuance of common stock for warrant exercise	$ 22	70,437	0	70,459
Issuance of common stock for warrant exercise (in shares)	65,240
Issuance of common stock from 401K match	$ 1	9,799	0	9,800
Issuance of common stock from 401K match (in shares)	3,968
Net loss	$ 0	0	(3,985,408)	(3,985,408)
Balance at Mar. 31, 2020	$ 5,064	52,805,601	(32,923,113)	19,887,552
Balance (in shares) at Mar. 31, 2020	15,350,445
Balance at Dec. 31, 2020	$ 7,346	70,907,315	(43,785,085)	27,129,576
Balance (in shares) at Dec. 31, 2020	22,261,619
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	257,622	0	257,622
Issuance of common stock from 401K match	$ 0	35,747	0	35,747
Issuance of common stock from 401K match (in shares)	16,642
Net loss	$ 0	0	(3,048,618)	(3,048,618)
Balance at Mar. 31, 2021	$ 7,346	$ 71,200,684	$ (46,833,703)	$ 24,374,327
Balance (in shares) at Mar. 31, 2021	22,278,261

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (3,048,618)	$ (3,985,408)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	257,622	124,992
Stock-based 401K company common match	35,747	9,800
Depreciation expense	1,860	3,902
Operating lease expense	60,257	0
Changes in assets and liabilities:
Prepaid expenses and other assets	(721,849)	(570,916)
Accounts payable	(464,626)	1,358,983
Accrued expenses	119,473	122,551
Restructuring reserve	0	(228,298)
Operating lease liabilities	(42,057)	0
Net cash used in operating activities	(3,802,191)	(3,164,394)
Cash flows from financing activities:
Proceeds from exercise of warrants	0	70,459
Proceeds from issuance of common stock, net of issuance costs	0	11,970,002
Net cash provided by financing activities	0	12,040,461
Net increase (decrease) in cash and cash equivalents	(3,802,191)	8,876,067
Cash and cash equivalents at beginning of period	28,839,565	12,161,739
Cash and cash equivalents at end of period	$ 25,037,374	$ 21,037,806

XML 19 R7.htm IDEA: XBRL DOCUMENT

Nature of Operations	3 Months Ended
Nature of Operations	Mar. 31, 2021
Nature of Operations [Abstract]
Nature of Operations	Note 1 – Nature of Operations PDS Biotechnology Corporation, a Delaware corporation (the “Company” or “PDS”), is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines designed to overcome the well-established limitations of current immunotherapy technologies. PDS owns Versamune^®, a proprietary T-cell activating platform designed to train the immune system to better attack and destroy disease. When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune^® has been shown to induce, in vivo, large quantities of high-quality, highly potent polyfunctional CD8+ killer T-cells, a specific sub-type of CD8+ killer T-cell that is more effective at killing infected or target cells. Our immuno-oncology products can potentially be used as a component of combination products with other leading technologies to provide effective treatments across a range of cancer types. We believe our product candidates are of interest for potential in relation to Human Papillomavirus, or HPV,- associated cancers, melanoma, colorectal, lung, breast and prostate cancers or as monotherapies in early-stage disease. PDS is working to expand its infectious disease pandemic development program, which includes novel vaccines for COVID-19 and universal influenza. From the Company’s inception, it has devoted substantially all of its efforts to drug development, business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital. On March 15, 2019, the Company, then operating as Edge Therapeutics, Inc. (“Edge”), completed its reverse merger with privately held PDS Biotechnology Corporation (“Private PDS”), pursuant to and in accordance with the terms of the Agreement and Plan of Merger, dated as of November 23, 2018, as amended on January 24, 2019, by and among the Company, Echos Merger Sub, a wholly-owned subsidiary of the Company (“Merger Sub”), and Private PDS, whereby Private PDS merged with and into Merger Sub, with Private PDS surviving as the Company’s wholly-owned subsidiary (the “Merger”). In connection with and immediately following completion of the Merger, the Company effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) and changed its corporate name from Edge Therapeutics, Inc. to PDS Biotechnology Corporation, and Private PDS changed its name to PDS Operating Corporation. For accounting purposes, the Merger was treated as a “reverse acquisition” under generally accepted accounting principles in the United States (“U.S. GAAP”) and Private PDS is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Private PDS became the Company’s historical financial statements, and the historical financial statements of Private PDS are included in the comparative prior periods. As part of the Merger, the Company acquired all of Edge’s assets relating to current and future research and development. In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a pandemic and on March 13 the President declared a national emergency in response to the pandemic. The full impact of the COVID-19 pandemic is unknown and rapidly evolving. The COVID-19 pandemic has and could continue to negatively affect the Company’s liquidity and operations. To date, two of the three recently initiated PDS0101 clinical trials were delayed, specifically as a result of the adverse impact the COVID-19 pandemic has had on clinical trial operations for cancer indications in the United States. The FDA issued and since updated guidance to assist sponsors in assuring the safety of trial participants, maintaining compliance with Good Clinical Practice (GCP) and minimizing risks to trial integrity. Clinical trial sites have implemented institution-specific measures securing the safety of patients and staff to ensure the integrity of the trials in the face of the ongoing pandemic. All three studies have since been initiated despite the pandemic challenges; however, the evolving COVID-19 pandemic has impacted the pace of enrollment in clinical trials in general and we may be negatively affected with our trials. COVID-19 related travel and other restrictions may also impact the potential for on-site monitoring visiting and audits and inspections by us, third parties, and regulators. There may be shortages of site personnel and equipment necessary for the timely completion of our trials. We are providing support to address these challenges, but these mitigation measures may not overcome the obstacles that the pandemic has wrought which continue to impede progress of clinical trials. Although there is uncertainty related to the anticipated impact of the COVID-19 pandemic on our future results, we believe our current cash reserves, leave us well-positioned to manage our business through this crisis as it continues to unfold. However, the impacts of the COVID-19 pandemic are broad-reaching and continuing and the financial impacts associated with the COVID-19 pandemic are still uncertain. Despite the economic uncertainty resulting from the COVID-19 pandemic, we intend to continue to focus on the development of our product candidates and we have expanded our infectious disease pipeline since the pandemic brought renewed resources and interest in technologies such as the Versamune® platform in the context of research and development in prevention of COVID-19. We are working with a consortium of partners in Brazil to develop PDS0203; a vaccine for the prevention of COVID-19. This consortium received a commitment from the Secretary for Research and Scientific Training of The Ministry of Science, Technology and Innovation of Brazil to fund up to approximately US$60 million to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2021

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

(A)	Unaudited interim financial statements:

(B)	Use of estimates:

(C)	Significant risks and uncertainties:

(D)	Cash equivalents and concentration of cash balance:

(E)	Research and development:

(F)	Patent costs:

The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.

(G)	Stock-based compensation:

In lieu of higher cash compensation, the Company has granted non-employee options to consultants and expensed $344 and $0 during the three months ended March 31, 2021 and 2020, respectively.

(H)	Net income (loss) per common share:

The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:

	As of March 31,
	2021		2020
Stock options to purchase Common Stock		1,899,193		1,413,073
Warrants to purchase Common Stock		197,518		197,518
Total		2,096,711		1,610,591

XML 21 R9.htm IDEA: XBRL DOCUMENT

Liquidity	3 Months Ended
Liquidity	Mar. 31, 2021
Liquidity [Abstract]
Liquidity	Note 3 – Liquidity As of March 31, 2021, the Company had $25.0 million of cash and cash equivalents. The Company’s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change to the Company’s outstanding accounts payable and accrued expenses. On July 29, 2019, we entered into a common stock purchase agreement, or the Aspire Purchase Agreement, with Aspire Capital pursuant to which, we have the right, in our sole discretion, to present Aspire Capital Fund, LLC, or Aspire Capital, with a purchase notice, directing Aspire Capital (as principal) to purchase up to 100,000 shares of our common stock per business day, in an aggregate amount of up to $20.0 million of our common stock, or the Purchased Shares, over the term of the Aspire Purchase Agreement. We may sell an aggregate of 1,034,979 shares of our common stock (which represented 19.99% of our outstanding shares of common stock on the date of the Aspire Purchase Agreement) without stockholder approval. We may sell additional shares of our common stock above the 19.99% limit provided that (i) we obtain stockholder approval or (ii) stockholder approval has not been obtained at any time the 1,034,979 share limitation is reached and at all times thereafter the average price paid for all shares issued under the Aspire Purchase Agreement, is equal to or greater than $5.76, which was the consolidated closing bid price of our common stock on July 26, 2019. The minimum price at which we can sell shares under the Aspire Purchase Agreement is $0.50. On July 29, 2019, we issued 100,654 shares of our common stock to Aspire Capital, as consideration for entering into the Aspire Purchase Agreement, which we refer to as the Commitment Shares. We recorded the fair value of the shares at July 29, 2019 of $603,924 as an expense in the third quarter of 2019. Concurrently with the Aspire Purchase Agreement, we entered into a registration rights agreement with Aspire Capital, or the Registration Rights Agreement. In accordance with the Registration Rights Agreement, on August 20, 2019 we filed a Registration Statement on Form S-1 (File No. 333-232988) to cover the resale of the Commitment Shares and any Purchased Shares issuable to Aspire Capital under the Aspire Purchase Agreement. There is market uncertainty regarding the utilization of financing associated from the Aspire Purchase Agreement. As of March 31, 2021, no Purchase Shares have been sold to Aspire Capital under the Aspire Purchase Agreement. In February 2020, we completed an underwritten public offering, in which we sold 10,000,000 shares of common stock at a public offering price of $1.30 per share. The shares sold included 769,230 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $13 million and net proceeds of approximately $11.9 million after deducting underwriting discounts and commissions. In July 2020, we filed a shelf registration statement, or the 2020 Shelf Registration Statement, with the SEC, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, which we refer to collectively as the Shelf Securities, up to an aggregate amount of $100 million. The 2020 Shelf Registration Statement was declared effective on July 31, 2020. On August 13, 2020, the Company sold 6,900,000 shares of its common stock at a public offering price of $2.75 per share pursuant to the 2020 Shelf Registration Statement, which includes 900,000 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $19.0 million and net proceeds of approximately $17.1 million, after deducting underwriting discounts and offering expenses. Approximately $81,000,000 of Shelf Securities remain available for future sale under the 2020 Shelf Registration Statement. Our primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Our budgeted cash requirements in 2021 and beyond include expenses related to continuing development and clinical studies. Based on our available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, we believe there are sufficient funds to continue operations and research and development programs for at least 12 months from the date of this report. We plan to continue to fund our operations and capital funding needs through equity and/or debt financings. However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders. We may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market immunotherapies that we would otherwise prefer to develop and market ourselves. Any of these actions could harm our business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect its ability to operate as a going concern.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2021

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

Note 4 – Fair Value of Financial Instruments

There were no transfers among Levels 1, 2, or 3 during 2021 or 2020.

	Fair Value Measurements at Reporting Date Using
	Total		Quoted Prices in Active Markets (Level 1)		Quoted Prices in Inactive Markets (Level 2)		Significant Unobservable Inputs (Level 3)
As of March 31, 2021: (unaudited)
Cash and cash equivalents	$	25,037,374	$	25,037,374	$	–	$	–

As of December 31, 2020
Cash and cash equivalents	$	28,839,565	$	28,839,565	$	–	$	–

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

Leases

Note 5 – Leases

Supplemental cash flow information related to operating leases is as follows:

	As of March 31,
	2021		2020
Cash paid for operating lease liabilities	$	42,057	$	-
Right-of use assets recorded in exchange for lease obligations	$	-	$	-

Maturity of the Company’s operating lease liability is as follows:

Year ended December 31,
2021 (remaining nine months)	$	128,779
2022		295,346
2023		239,469
2024		-
2025 and after		-
Total future minimum lease payments		663,594
Less inputed interest		(81,649	)
	$	581,945

XML 24 R12.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2021

Accrued Expenses [Abstract]

Accrued Expenses

Note 6 – Accrued Expenses

Accrued expenses and other liabilities consist of the following:

	As of March 31, 2021		As of December 31, 2020
Accrued research and development costs	$	23,900	$	204,780
Accrued professional fees		320,266		219,822
Accrued compensation		1,510,629		1,310,720
Total	$	1,854,795	$	1,735,322

XML 25 R13.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2021

Stock-Based Compensation [Abstract]

Stock-Based Compensation

Note 7 – Stock-Based Compensation

The Company has three equity compensation plans: the 2009 Stock Option Plan, 2014 Equity Incentive Plan and the 2018 Stock Incentive Plan (the “Plans”).

The Company’s stock-based compensation expense was recognized in operating expense as follows:

	Three Months Ended March 31,
	2021		2020
	(unaudited)
Stock-Based Compensation
Research and development	$	60,385	$	52,684
General and administrative		197,236		72,308
Total	$	257,622	$	124,992

The fair value of options and warrants granted during the three months ended March 31, 2021 was estimated using the Black-Scholes option valuation model utilizing the following assumptions:

	Three Months Ended March 31,
	2021			2020
	Weighted Average			Weighted Average
	(unaudited)
Volatility		100.38	%		92.56	%
Risk-Free Interest Rate		0.35	%		1.56	%
Expected Term in Years		5.82			6.01
Dividend Rate		0.00	%		0.00	%
Fair Value of Option on Grant Date	$	1.73		$	0.99

The following table summarizes the number of options outstanding and the weighted average exercise price:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Options outstanding at December 31, 2020		1,650,897		$	11.87
Granted		267,800			2.32
Exercised		–			–
Forfeited		(19,500	)		23.87
Expired		–			–
Options outstanding at March 31, 2021		1,899,197		$	10.40		7.2	$	1,654,588
Vested and expected to vest at March 31, 2021		1,899,197		$	10.40		7.2	$	1,654,588
Exercisable at March 31, 2021		1,167,963		$	15.10		5.52	$	157,569

At March 31, 2021 there was approximately $1,483,195 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 3 years.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2021
Income Taxes [Abstract]
Income Taxes	Note 8 – Income Taxes In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for 2021 and there will be no current income tax expense. Additionally, there was a full valuation allowance against the net deferred tax assets as of March 31, 2021 and December 31, 2020. As such, the Company recorded no income tax benefit due to realization uncertainties. The Company’s U.S. statutory rate is 21%. The primary factor impacting the effective tax rate for the three months ended March 31, 2021 is the anticipated full year operating loss which will require full valuation allowances against any associated net deferred tax assets. Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of March 31, 2021, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the three months ended March 31, 2021 and for the year ended December 31, 2020.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 27 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2021
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Rent For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three months ended March 31, 2021 and 2020, rent was $36,017 and $58,641 respectively.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Retirement Plan	3 Months Ended
Retirement Plan	Mar. 31, 2021
Retirement Plan [Abstract]
Retirement Plan	Note 10 – Retirement Plan The Company has a 401(k) defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $35,747 and $9,800 for the three months ended March 31, 2021 and 2020, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

+ Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 11– Subsequent Events Subsequent events have been evaluated through the date these financial statements were issued.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2021

Summary of Significant Accounting Policies [Abstract]

Unaudited Interim Financial Statements

(A)	Unaudited interim financial statements:

Use of Estimates

(B)	Use of estimates:

Significant Risks and Uncertainties

(C)	Significant risks and uncertainties:

Cash Equivalents and Concentration of Cash Balance

(D)	Cash equivalents and concentration of cash balance:

Research and Development

(E)	Research and development:

Patent Costs

(F)	Patent costs:

The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.

Stock-Based Compensation

(G)	Stock-based compensation:

In lieu of higher cash compensation, the Company has granted non-employee options to consultants and expensed $344 and $0 during the three months ended March 31, 2021 and 2020, respectively.

Net Income (Loss) per Common Share

(H)	Net income (loss) per common share:

The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:

	As of March 31,
	2021		2020
Stock options to purchase Common Stock		1,899,193		1,413,073
Warrants to purchase Common Stock		197,518		197,518
Total		2,096,711		1,610,591

XML 31 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2021

Summary of Significant Accounting Policies [Abstract]

Antidilutive Securities

The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:

	As of March 31,
	2021		2020
Stock options to purchase Common Stock		1,899,193		1,413,073
Warrants to purchase Common Stock		197,518		197,518
Total		2,096,711		1,610,591

XML 32 R20.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2021

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

	Fair Value Measurements at Reporting Date Using
	Total		Quoted Prices in Active Markets (Level 1)		Quoted Prices in Inactive Markets (Level 2)		Significant Unobservable Inputs (Level 3)
As of March 31, 2021: (unaudited)
Cash and cash equivalents	$	25,037,374	$	25,037,374	$	–	$	–

As of December 31, 2020
Cash and cash equivalents	$	28,839,565	$	28,839,565	$	–	$	–

XML 33 R21.htm IDEA: XBRL DOCUMENT

Leases (Tables)

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

Supplemental Cash Flow Information Related to Operating Leases

Supplemental cash flow information related to operating leases is as follows:

	As of March 31,
	2021		2020
Cash paid for operating lease liabilities	$	42,057	$	-
Right-of use assets recorded in exchange for lease obligations	$	-	$	-

Future Payments for Operating Lease Liabilities

Maturity of the Company’s operating lease liability is as follows:

Year ended December 31,
2021 (remaining nine months)	$	128,779
2022		295,346
2023		239,469
2024		-
2025 and after		-
Total future minimum lease payments		663,594
Less inputed interest		(81,649	)
	$	581,945

XML 34 R22.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2021

Accrued Expenses [Abstract]

Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following:

	As of March 31, 2021		As of December 31, 2020
Accrued research and development costs	$	23,900	$	204,780
Accrued professional fees		320,266		219,822
Accrued compensation		1,510,629		1,310,720
Total	$	1,854,795	$	1,735,322

XML 35 R23.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2021

Stock-Based Compensation [Abstract]

Stock-Based Compensation Expense

The Company’s stock-based compensation expense was recognized in operating expense as follows:

	Three Months Ended March 31,
	2021		2020
	(unaudited)
Stock-Based Compensation
Research and development	$	60,385	$	52,684
General and administrative		197,236		72,308
Total	$	257,622	$	124,992

Assumptions Used to Value Stock Options and Warrants Granted

The fair value of options and warrants granted during the three months ended March 31, 2021 was estimated using the Black-Scholes option valuation model utilizing the following assumptions:

	Three Months Ended March 31,
	2021			2020
	Weighted Average			Weighted Average
	(unaudited)
Volatility		100.38	%		92.56	%
Risk-Free Interest Rate		0.35	%		1.56	%
Expected Term in Years		5.82			6.01
Dividend Rate		0.00	%		0.00	%
Fair Value of Option on Grant Date	$	1.73		$	0.99

Stock Option Activity

The following table summarizes the number of options outstanding and the weighted average exercise price:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Options outstanding at December 31, 2020		1,650,897		$	11.87
Granted		267,800			2.32
Exercised		–			–
Forfeited		(19,500	)		23.87
Expired		–			–
Options outstanding at March 31, 2021		1,899,197		$	10.40		7.2	$	1,654,588
Vested and expected to vest at March 31, 2021		1,899,197		$	10.40		7.2	$	1,654,588
Exercisable at March 31, 2021		1,167,963		$	15.10		5.52	$	157,569

XML 36 R24.htm IDEA: XBRL DOCUMENT

Nature of Operations (Details) $ in Millions		3 Months Ended
Nature of Operations (Details) $ in Millions	Mar. 15, 2019	Mar. 31, 2021 USD ($) ClinicalTrial
Nature of Operations [Abstract]
Reverse stock split ratio	0.05
Number of planned clinical trials delayed		2
Number of planned clinical trials		3
Ministry of Science, Technology and Innovation of Brazil [Member] \| Clinical Development and Commercialization of COVID-19 Vaccine [Member]
Nature of Operations [Abstract]
Committed funding to COVID-19 vaccine consortium \| $		$ 60

XML 37 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net Income (Loss) per Common Share [Abstract]
Antidilutive impact to EPS (in shares)	2,096,711	1,610,591
Nonemployee Consultants [Member]
Stock-Based Compensation [Abstract]
Options granted	$ 344	$ 0
Stock Options to Purchase Common Stock [Member]
Net Income (Loss) per Common Share [Abstract]
Antidilutive impact to EPS (in shares)	1,899,193	1,413,073
Warrants to Purchase Common Stock [Member]
Net Income (Loss) per Common Share [Abstract]
Antidilutive impact to EPS (in shares)	197,518	197,518

XML 38 R26.htm IDEA: XBRL DOCUMENT

Liquidity (Details) - USD ($)			1 Months Ended	3 Months Ended
Liquidity (Details) - USD ($)	Aug. 13, 2020	Jul. 29, 2019	Feb. 29, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Jul. 31, 2020	Jul. 26, 2019
Liquidity [Abstract]
Cash and cash equivalents				$ 25,037,374		$ 28,839,565
Percentage of shares of common stock that can be sold without shareholder approval		19.99%
Share price (in dollars per share)								$ 5.76
Issuance of common stock from equity transaction (in shares)		100,654
Issuance of common stock from equity transaction		$ 603,924
Shares sold under common stock purchase agreement (in shares)				0
Issuance of common stock (in shares)	6,900,000		10,000,000
Sales price (in dollars per share)	$ 2.75		$ 1.30
Proceeds from issuance of shares	$ 19,000,000		$ 13,000,000	$ 0	$ 11,970,002
Proceeds from issuance of shares, net of underwriting discounts and commissions	$ 17,100,000		$ 11,900,000
Registered securities in Shelf Registration Statement available for future sale							$ 100,000,000
Shelf securities available for sale				$ 81,000,000
Over-Allotment Option [Member]
Liquidity [Abstract]
Issuance of common stock (in shares)	900,000		769,230
Maximum [Member]
Liquidity [Abstract]
Shares of common stock to be purchased (in shares)		100,000
Common stock to be purchased under common stock purchase agreement		$ 20,000,000
Shares of common stock that can be sold without shareholder approval (in shares)		1,034,979
Minimum [Member]
Liquidity [Abstract]
Share price (in dollars per share)								$ 0.50

XML 39 R27.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Details) - USD ($)	3 Months Ended	12 Months Ended
Fair Value of Financial Instruments (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Fair Value Transfers Between Levels [Abstract]
Transfers from Level 1 to Level 2	$ 0	$ 0
Transfers from Level 2 to Level 1	0	0
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents	25,037,374	28,839,565
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents	25,037,374	28,839,565
Quoted Prices in Inactive Markets (Level 2) [Member]
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents	$ 0	$ 0

XML 40 R28.htm IDEA: XBRL DOCUMENT

Leases, Operating Leases (Details)	Mar. 31, 2021 USD ($) ft²	Dec. 31, 2020 USD ($)	May 01, 2020 USD ($)	Jul. 08, 2019 USD ($) Installment
Leases [Abstract]
Percentage of remaining payments required to be paid to terminate lease				50.00%
Remaining lease payments				$ 665,802
Number of installments for remaining lease payment \| Installment				3
Area of office space under sub-lease \| ft²	11,200
Term of sub-lease agreement	40 months
Remaining lease term	29 months
Right-of-use asset	$ 501,194	$ 547,706	$ 700,000
Operating lease liability	$ 581,945		$ 700,000
Discount rate used to measure operating lease liability			9.15%

XML 41 R29.htm IDEA: XBRL DOCUMENT

Leases, Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Supplemental Cash Flow Information Related to Operating Leases [Abstract]
Cash paid for operating lease liabilities	$ 42,057	$ 0
Right-of use assets recorded in exchange for lease obligations	$ 0	$ 0

XML 42 R30.htm IDEA: XBRL DOCUMENT

Leases, Future Payments for Operating Lease Liabilities (Details) - USD ($)	Mar. 31, 2021	May 01, 2020
Future Payments for Operating Lease Liabilities [Abstract]
2021 (remaining nine months)	$ 128,779
2022	295,346
2023	239,469
2024	0
2025 and after	0
Total future minimum lease payments	663,594
Less imputed interest	(81,649)
Lease liability	$ 581,945	$ 700,000

XML 43 R31.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Accrued Expenses [Abstract]
Accrued research and development costs	$ 23,900	$ 204,780
Accrued professional fees	320,266	219,822
Accrued compensation	1,510,629	1,310,720
Total	$ 1,854,795	$ 1,735,322

XML 44 R32.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation, Equity Compensation Plans (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2021 Plan shares	Dec. 31, 2014 shares	Dec. 09, 2020 shares	Dec. 08, 2020 shares	Mar. 31, 2019 shares	Dec. 31, 2018 shares
Stock Options [Abstract]
Number of equity compensation plans \| Plan	3
The Plans [Member]
Stock Options [Abstract]
Term of plan	10 years
The Plans [Member] \| Incentive Stock Options [Member]
Stock Options [Abstract]
Vesting period	4 years
The Plans [Member] \| Incentive Stock Options [Member] \| Maximum [Member]
Stock Options [Abstract]
Term of option	10 years
The Plans [Member] \| Nonqualified Options [Member] \| Minimum [Member]
Stock Options [Abstract]
Vesting period	1 year
The Plans [Member] \| Nonqualified Options [Member] \| Maximum [Member]
Stock Options [Abstract]
Vesting period	5 years
2014 Equity Incentive Plan [Member]
Stock Options [Abstract]
Number of shares authorized for issuance (in shares)		91,367			826,292
Percentage of Common Stock outstanding used to determine annual increase in the plan limit		4.00%
2018 Equity Incentive Plan [Member]
Stock Options [Abstract]
Number of shares authorized for issuance (in shares)						558,071
Shares available for grant (in shares)	190,799
2019 Inducement Plan [Member]
Stock Options [Abstract]
Shares available for grant (in shares)	221,200
Common stock reserved for issuance (in shares)			500,000	200,000

XML 45 R33.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-Based Compensation [Abstract]
Stock-based compensation expense	$ 257,622	$ 124,992
Research and Development [Member]
Stock-Based Compensation [Abstract]
Stock-based compensation expense	60,385	52,684
General and Administrative [Member]
Stock-Based Compensation [Abstract]
Stock-based compensation expense	$ 197,236	$ 72,308

XML 46 R34.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Assumptions Used in Determining Fair Value of Stock Options Granted [Abstract]
Volatility	100.38%	92.56%
Risk-free interest rate	0.35%	1.56%
Expected term	5 years 9 months 25 days	6 years 4 days
Dividend rate	0.00%	0.00%
Fair value of option on grant date (in dollars per share)	$ 1.73	$ 0.99

XML 47 R35.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation, Stock Option Activity (Details) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2021 USD ($) $ / shares shares
Number of Shares [Roll Forward]
Options outstanding, beginning balance (in shares) \| shares	1,650,897
Granted (in shares) \| shares	267,800
Exercised (in shares) \| shares	0
Forfeited (in shares) \| shares	(19,500)
Expired (in shares) \| shares	0
Options outstanding, ending balance (in shares) \| shares	1,899,197
Vested and expected to vest (in shares) \| shares	1,899,197
Exercisable (in shares) \| shares	1,167,963
Weighted Average Exercise Price [Roll Forward]
Options outstanding, beginning balance (in dollars per share) \| $ / shares	$ 11.87
Granted (in dollars per share) \| $ / shares	2.32
Exercised (in dollars per share) \| $ / shares	0
Forfeited (in dollars per share) \| $ / shares	23.87
Expired (in dollars per share) \| $ / shares	0
Options outstanding, ending balance (in dollars per share) \| $ / shares	10.40
Vested and expected to vest (in dollars per share) \| $ / shares	10.40
Exercisable (in dollars per share) \| $ / shares	$ 15.10
Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]
Options outstanding, weighted average remaining contractual life	7 years 2 months 12 days
Vested and expected to vest, weighted average remaining contractual life	7 years 2 months 12 days
Exercisable, weighted average remaining contractual life	5 years 6 months 7 days
Options outstanding, aggregate intrinsic value \| $	$ 1,654,588
Vested and expected to vest, aggregate intrinsic value \| $	1,654,588
Exercisable, aggregate intrinsic value \| $	157,569
Unamortized Stock Compensation Expense [Abstract]
Unamortized stock compensation expense \| $	$ 1,483,195
Period for recognition	3 years

XML 48 R36.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	3 Months Ended
Income Taxes (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Current income tax expense	$ 0
Income tax benefit	$ 0
Federal statutory rate	21.00%
Uncertain tax positions	$ 0
Unrecognized tax benefits	0	$ 0
Accrued interest and penalties	$ 0	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 49 R37.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($)	3 Months Ended
Commitments and Contingencies (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Commitments and Contingencies [Abstract]
Rent expense	$ 36,017	$ 58,641

XML 50 R38.htm IDEA: XBRL DOCUMENT

Retirement Plan (Details) - USD ($)	3 Months Ended
Retirement Plan (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Retirement Plan [Abstract]
401(k) employer contribution	$ 35,747	$ 9,800

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ʃ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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 74 266 1 false 23 0 false 8 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://pdsbiotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - Condensed Consolidated Balance Sheets Sheet http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity Sheet http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 040000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 060100 - Disclosure - Nature of Operations Sheet http://pdsbiotech.com/role/NatureOfOperations Nature of Operations Notes 7 false false R8.htm 060200 - Disclosure - Summary of Significant Accounting Policies Sheet http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 060300 - Disclosure - Liquidity Sheet http://pdsbiotech.com/role/Liquidity Liquidity Notes 9 false false R10.htm 060400 - Disclosure - Fair Value of Financial Instruments Sheet http://pdsbiotech.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 060500 - Disclosure - Leases Sheet http://pdsbiotech.com/role/Leases Leases Notes 11 false false R12.htm 060600 - Disclosure - Accrued Expenses Sheet http://pdsbiotech.com/role/AccruedExpenses Accrued Expenses Notes 12 false false R13.htm 060700 - Disclosure - Stock-Based Compensation Sheet http://pdsbiotech.com/role/StockbasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 060800 - Disclosure - Income Taxes Sheet http://pdsbiotech.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 060900 - Disclosure - Commitments and Contingencies Sheet http://pdsbiotech.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 061000 - Disclosure - Retirement Plan Sheet http://pdsbiotech.com/role/RetirementPlan Retirement Plan Notes 16 false false R17.htm 061100 - Disclosure - Subsequent Events Sheet http://pdsbiotech.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 070200 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 080200 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 080400 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://pdsbiotech.com/role/FairValueOfFinancialInstruments 20 false false R21.htm 080500 - Disclosure - Leases (Tables) Sheet http://pdsbiotech.com/role/LeasesTables Leases (Tables) Tables http://pdsbiotech.com/role/Leases 21 false false R22.htm 080600 - Disclosure - Accrued Expenses (Tables) Sheet http://pdsbiotech.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://pdsbiotech.com/role/AccruedExpenses 22 false false R23.htm 080700 - Disclosure - Stock-Based Compensation (Tables) Sheet http://pdsbiotech.com/role/StockbasedCompensationTables Stock-Based Compensation (Tables) Tables http://pdsbiotech.com/role/StockbasedCompensation 23 false false R24.htm 090100 - Disclosure - Nature of Operations (Details) Sheet http://pdsbiotech.com/role/NatureOfOperationsDetails Nature of Operations (Details) Details http://pdsbiotech.com/role/NatureOfOperations 24 false false R25.htm 090200 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 090300 - Disclosure - Liquidity (Details) Sheet http://pdsbiotech.com/role/LiquidityDetails Liquidity (Details) Details http://pdsbiotech.com/role/Liquidity 26 false false R27.htm 090400 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables 27 false false R28.htm 090500 - Disclosure - Leases, Operating Leases (Details) Sheet http://pdsbiotech.com/role/LeasesOperatingLeasesDetails Leases, Operating Leases (Details) Details 28 false false R29.htm 090502 - Disclosure - Leases, Supplemental Cash Flow Information Related to Operating Leases (Details) Sheet http://pdsbiotech.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails Leases, Supplemental Cash Flow Information Related to Operating Leases (Details) Details 29 false false R30.htm 090504 - Disclosure - Leases, Future Payments for Operating Lease Liabilities (Details) Sheet http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails Leases, Future Payments for Operating Lease Liabilities (Details) Details 30 false false R31.htm 090600 - Disclosure - Accrued Expenses (Details) Sheet http://pdsbiotech.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://pdsbiotech.com/role/AccruedExpensesTables 31 false false R32.htm 090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details) Sheet http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails Stock-Based Compensation, Equity Compensation Plans (Details) Details 32 false false R33.htm 090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details) Sheet http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details) Details 33 false false R34.htm 090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details) Sheet http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details) Details 34 false false R35.htm 090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details) Sheet http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails Stock-Based Compensation, Stock Option Activity (Details) Details 35 false false R36.htm 090800 - Disclosure - Income Taxes (Details) Sheet http://pdsbiotech.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://pdsbiotech.com/role/IncomeTaxes 36 false false R37.htm 090900 - Disclosure - Commitments and Contingencies (Details) Sheet http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://pdsbiotech.com/role/CommitmentsAndContingencies 37 false false R38.htm 091000 - Disclosure - Retirement Plan (Details) Sheet http://pdsbiotech.com/role/RetirementPlanDetails Retirement Plan (Details) Details http://pdsbiotech.com/role/RetirementPlan 38 false false All Reports Book All Reports pdsb-20210331.xml pdsb-20210331.xsd pdsb-20210331_cal.xml pdsb-20210331_def.xml pdsb-20210331_lab.xml pdsb-20210331_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 56 0001140361-21-017113-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-21-017113-xbrl.zip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end